藥品代碼,適用族群(成人/兒童),檢驗方式,下限,上限,下限單位,上限單位,建議,備註,新增時間,修改時間
EASA,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,嚴重腎功能不全者禁用(GFR值小於30毫升/每分鐘/1.73m2),仿單,202210241552,202210241554
EDDA,成人,Clcr,0,50.00,mL/min,mL/min,中度到嚴重的腎功能不全病患不建議使用,,201907241536,201804242350
EDUR1,成人,eGFR,30.00,0,mL/min/1.73m2,mL/min/1.73m2,Renal impairment (severe): Avoid use,Micromedex 20210714,202107141207,202107141205
EDUR1,成人,eGFR,60.00,30.00,mL/min/1.73m2,mL/min/1.73m2,Renal impairment (mild to moderate): Initiate with 50% of the usual dosage,Micromedex 20210714,202107141207,202107141205
EDUR2,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Mild-to-moderate impairment: Initial: Reduce dose by 50%. Severe impairment: Use not recommended.,,201805281457,
EFEN,成人,eGFR,30.00,0,mL/min/1.73m2,mL/min/1.73m2,Renal impairment (severe): Avoid use,Micromedex 20210714,202107141207,202107141205
EFEN,成人,eGFR,60.00,30.00,mL/min/1.73m2,mL/min/1.73m2,Renal impairment (mild to moderate): Initiate with 50% of the usual dosage,Micromedex 20210714,202107141207,202107141205
EOPI,成人,eGFR,30.00,0,mL/min/1.73m2,mL/min/1.73m2,Renal impairment (severe): Avoid use,Micromedex 20210714,202107141205,202107141205
EOPI,成人,eGFR,60.00,30.00,mL/min/1.73m2,mL/min/1.73m2,Renal impairment (mild to moderate): Initiate with 50% of the usual dosage,Micromedex 20210714,202107141200,202107141205
ESIM,成人,Clcr,0,29.99,mL/min,mL/min,Use is contraindicated.,,201806251600,201806251604
EVORS,成人,Clcr,0,30.00,mL/min,mL/min,Significant impairment or advanced renal disease: Use is not recommended.,,201912091137,201912091137
IACE,成人,Clcr,59.99,0,mL/min,mL/min,Reduced Dose at Fixed-Time Intervals  An alternative rough guide for calculating a reduced dose at a fixed 12-hour interval in patients with known steady-state serum creatinine values is to divide the normally recommended dose by the patient's serum creatinine.,Micromedex 20210708,202107081134,202107081135
IACE,成人,Clcr,60.00,0,mL/min,mL/min,Reduced Dose at Fixed-Time Intervals  If serum concentrations are not available and the patient condition is stable， use the serum creatinine and creatinine clearance (CrCl) values to guide dose adjustment.   To calculate the dose for a fixed-time interval administered every 12 hours (after administration of normal loading dose of 7.5 mg/kg)， reduce the normal loading dose in proportion to the reduction in CrCl rate as follows:  maintenance dose every 12 hours = observed CrCl (mL/min)/normal CrCl (mL/min) x 7.5 mg/body weight (kg),Micromedex 20210708,202107081125,202107081135
IACET,成人,Clcr,0,10.00,mL/min,mL/min,兩次用藥至少間隔8小時,,201804142321,201804142321
IACL,成人,Clcr,0,35.00,mL/min,mL/min,不建議使用,,201804111604,201804111604
IACTMV,成人,Clcr,0,60.00,mL/min,mL/min,不需為輕度或中度腎功能不全調整劑量.目前尚未針對重度腎功能不全者使用之療效與安全性研究.,仿單,202106231359,202106231400
IAGG,成人,Clcr,0,59.90,mL/min,mL/min,CrCl <60 mL/minute: IV Loading dose: 25 mcg/kg administered over 5 minutes or less; Maintenance infusion: 0.075 mcg/kg/minute continued for up to 18 hours,,201804191220,201910251156
IALF,成人,Clcr,0,0,mL/min,mL/min,腎功能不全的病患應謹慎使用並考慮降低劑量,,201804141456,201804141456
IALI1,成人,Clcr,0,45.00,mL/min,mL/min,禁止使用,,201804301510,
IALI5,成人,Clcr,0,45.00,mL/min,mL/min,禁止使用,,201804301511,
IAMI2,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Use with caution in patients with renal impairment; dosage adjustment may be necessary. Some products are contraindicated in patients with severe renal failure.,,201804231747,
IAMP,成人,Clcr,0,9.99,mL/min,mL/min,change interval to every 12 to 16 hours,,,
IAMP,成人,Clcr,10.00,50.00,mL/min,mL/min,change interval to every 6 to 12 hours,,,
IANO,成人,Clcr,0,0,mL/min,mL/min,嚴重腎臟疾病或進行性腎損害或腎功能障礙之完全無尿病患不建議使用,,201907091128,201907100812
IARI,成人,Clcr,0,29.90,mL/min,mL/min,Use is contraindicated.,,201804191142,
IARI,成人,Clcr,30.00,50.00,mL/min,mL/min,Use caution; total clearance ~40% lower compared to patients with normal renal function. When used for thromboprophylaxis， the American College of Chest Physicians suggests a 50% reduction in dose or use of low-dose heparin instead of fondaparinux.,,201804191142,
IBFL,成人,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,腎障礙的病患應謹慎使用,重症腎障礙或高氮血症患者不建議使用,201804261421,201804261421
IBIC,成人,eGFR,0,9.99,mL/min,mL/min,Administer 20% to 50% of the normal dose.,Micromedex Solutions. Accessed April 2， 2020.,201803281156,202004021546
IBIC,成人,eGFR,10.00,50.00,mL/min,mL/min,Administer 75% of the normal dose.,Micromedex Solutions. Accessed April 2， 2020.,201803281156,202004021546
IBLE1,成人,Clcr,0,30.00,mL/min,mL/min,嚴重腎功能不全者為禁忌,,201804301537,
IBOL,成人,Clcr,0,30.00,mL/min,mL/min,不建議使用,,201804112354,201804112354
IBOL,成人,Clcr,30.00,39.00,mL/min,mL/min,調整成 3.0mg,,201804112354,
IBOL,成人,Clcr,40.00,49.00,mL/min,mL/min,調整成 3.3mg,,201804112354,
IBOL,成人,Clcr,50.00,60.00,mL/min,mL/min,調整成 3.5mg,,201804112353,
IBON,成人,Clcr,0,12.00,mL/min,mL/min,劑量減少50%,,201804112356,201804112356
IBON,成人,Clcr,12.00,50.00,mL/min,mL/min,劑量減少25%~50%,,201804112356,
IBON,成人,Clcr,50.00,80.00,mL/min,mL/min,劑量減少25%,,201804112356,
IBONV,成人,Clcr,0,30.00,mL/min,mL/min,不建議使用,,201804112358,201804112358
IBRID,成人,Clcr,0,30.00,mL/min,mL/min,不建議使用,,201804191446,201804191446
ICAG,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Initiate with the lower limit of the dosage range (accumulation may occur with renal impairment and subsequent doses may require adjustment based on serum calcium concentrations).,,201804231738,201804231738
ICEF1,成人,Clcr,0,0,mL/min,mL/min,Hemodialysis: 1 -2 gm Q24-48H (+ extra 0.5-1 gm after dialysis),,,
ICEF1,成人,Clcr,0,10.00,mL/min,mL/min,1 -2 gm Q24-48H,,,
ICEF1,成人,Clcr,10.00,50.00,mL/min,mL/min,1 -2 gm Q12H,,,
ICEF1,成人,Clcr,50.00,90.00,mL/min,mL/min,1 -2 gm Q8H,,,
ICEF1,兒童,Clcr,5.00,20.00,mL/min,mL/min,10% of the normal daily dose given every 24 hr,,201803261632,201803261632
ICEF1,兒童,Clcr,20.00,40.00,mL/min,mL/min,25% of the normal dose divided every 12 hr,,201803261632,201803261632
ICEF1,兒童,Clcr,40.00,70.00,mL/min,mL/min,60% of the normal daily dose divided every 12 hr,,201803261632,
ICEFT,成人,Clcr,0,0,mL/min,mL/min,give initial 1 g loading dose followed by 1 g after each hemodialysis period,血液透析患者,201803261636,
ICEFT,成人,Clcr,0,5.00,mL/min,mL/min,0.5 g every 48 hours,,201803261635,
ICEFT,成人,Clcr,6.00,15.00,mL/min,mL/min,0.5 g every 24 hours,,201803261635,
ICEFT,成人,Clcr,16.00,30.00,mL/min,mL/min,1 g every 24 hours,,201803261635,
ICEFT,成人,Clcr,31.00,50.00,mL/min,mL/min,1 g every 12 hours,,201803261634,
ICERE,成人,Clcr,0,0,mL/min,mL/min,嚴重腎功能不全患者不建議使用,,201804261423,201804261423
ICET,成人,eGFR,0,9.99,mL/min/1.73m2,mL/min/1.73m2,1-2 g every 48 hours (after hemodialysis),Micromedex,201803261642,202011111046
ICET,成人,eGFR,10.00,29.00,mL/min/1.73m2,mL/min/1.73m2,1-2 g every 24 hours,Micromedex,201803261640,202011111047
ICET,成人,eGFR,30.00,49.00,mL/min/1.73m2,mL/min/1.73m2,1-2 g every 16 hours,Micromedex,201803261640,202011111047
ICET,成人,eGFR,50.00,90.00,mL/min/1.73m2,mL/min/1.73m2,1-2 g every 12 hours,Micromedex,201803261640,202011111047
ICETR,成人,Clcr,0,10.00,mL/min,mL/min,重度腎功能不全者不建議使用,無相關研究應謹慎使用,201804231429,201810211205
ICIP2,成人,Clcr,0,4.00,mL/min,mL/min,依上述Clcr值調整，於透析完再給藥,,,
ICIP2,成人,Clcr,5.00,29.00,mL/min,mL/min,200 to 400 mg IV every 18 to 24 hours,400mg/day,,
ICIP2,成人,Clcr,30.00,120.00,mL/min,mL/min,無須調整劑量,800mg/day,,
ICIT3,成人,Clcr,0,0,mL/min,mL/min,嚴重腎功能障礙者應謹慎使用,,201804191527,201804191527
ICLA1,成人,eGFR,0,20.00,mL/min/1.73m2,mL/min/1.73m2,Dose should be reduced by 50%,MICROMEDEX (2020-05-26),202005261654,202005261649
ICLA1,成人,Clcr,0,0,mL/min,mL/min,H/D: 1 ~ 2g q24h AD CAPD: 1 ~ 2g q24h,仿單,202005261647,202005261649
ICLA1,成人,Clcr,0,10.00,mL/min,mL/min,1 - 2gm q24h,Sanford Guide(Web) (2020-05-26),202005261658,202005261649
ICLA1,成人,Clcr,0,9.99,mL/min,mL/min,Loading dose: 1g; Maintenance dose: 50% of normal dose with same freqency,仿單,202005261644,
ICLA1,成人,Clcr,10.00,50.00,mL/min,mL/min,1 - 2gm q12-24h,Sanford Guide(Web) (2020-05-26),202005261657,202005261649
ICLAR2,成人,Clcr,0,30.00,mL/min,mL/min,[仿單]重度腎功能不全（GFR<30mL/min/1.73m2），應先謹慎評估，如果必須使用，每公斤體重的注射劑量不可超過 0.1 mmol/kg。每次掃描之注射不可超過一次。,,202001121050,202001121053
ICLEX,成人,Clcr,0,30.00,mL/min,mL/min,DVT prophylaxis in abdominal surgery， hip replacement， knee replacement， or in medical patients during acute illness: SubQ: 30 mg once daily.,,201804191144,
ICLI15,成人,Clcr,0,0,mL/min,mL/min,對於腎功能不全患者，應該謹慎注意,嚴重腎功能衰竭 嚴重腎功能衰竭患者最好使用特殊配方的氨基酸溶液,201804261519,201804261519
ICOL,成人,Scr,0.70,1.20,mg/dL,mg/dL,100-150mg Q6H-Q12H， approximate daily dose = 5mg/kg/day,300mg/day,,
ICOL,成人,Scr,1.30,1.50,mg/dL,mg/dL,75-115mg Q12H， approximate daily dose = 2.5-3.8mg/kg/day,150-230mg/day,,
ICOL,成人,Scr,1.60,2.50,mg/dL,mg/dL,66-150mg Q12H-Q24H， approximate daily dose = 2.5mg/kg/day,133-150mg/day,,
ICOL,成人,Scr,2.60,4.00,mg/dL,mg/dL,100-150mg Q36H， approximate daily dose = 1.5mg/kg/day,100mg/day,,
ICOL,成人,Clcr,10.00,29.99,mL/min,mL/min,1.5 mg/kg IM or IV every 36 hours,,,
ICOL,成人,Clcr,30.00,49.99,mL/min,mL/min,2.5 mg/kg IM or IV once daily or in 2 divided doses,,,
ICOL,成人,Clcr,50.00,79.00,mL/min,mL/min,2.5 to 3.8 mg/kg/day IM or IV in 2 divided doses,,,
ICRA2,成人,Clcr,0,19.99,mL/min,mL/min,【熱病】: 750 mg once， then 500 mg q48h (Hemodialysis， CAPD， CRRT皆適用),,202112031347,202112031349
ICRA2,成人,Clcr,10.00,19.00,mL/min,mL/min,【250mg/day regimen】: 250mg q48h  【500mg/day regimen】: loading 500mg， then 250mg q48h 【750mg/day regimen】: loading 750mg， then 500mg q48h,,,201908291500
ICRA2,成人,Clcr,20.00,49.00,mL/min,mL/min,【250mg/day regimen】: no adjustment required  【500mg/day regimen】: loading 500mg， then 250mg q24h  【750mg/day regimen】: 750mg q48h 【熱病】: 750mg q48h,,,202112031348
ICRA2,成人,Clcr,50.00,120.00,mL/min,mL/min,無須調整劑量,,,
IDDA,成人,Clcr,0,50.00,mL/min,mL/min,中度到嚴重的腎功能不全病患不建議使用,資料來源:Micromedex,201907241538,201804242350
IDES,成人,Clcr,0,0,mL/min,mL/min,嚴重腎衰竭患者應小心使用，鐵和鋁的複合物之排除會因透析而增加，應考慮監測患者腎功能變化,,201804191458,201804191458
IDEXA,成人,Clcr,0,0,mL/min,mL/min,腎機能不全者不建議使用,,201804231401,201804231401
IDIF,成人,Clcr,10.00,20.99,mL/min,mL/min,正常劑量，給藥間隔為72小時，或正常每日劑量的三分之一，給藥間隔24小時,,,
IDIF,成人,Clcr,21.00,40.00,mL/min,mL/min,正常劑量，給藥間隔為48小時，或正常每日劑量的一半給藥間隔24小時,,,
IDIF,成人,Clcr,40.01,999.00,mL/min,mL/min,正常劑量，給藥間隔為24小時,,,
IDIG2,成人,Clcr,0,0,mL/min,mL/min,腎功能障礙及無尿排泄病人，半衰期可能延長至100小時，因此可能需要減少維持劑量。,,201804120018,201804120018
IDIPE,成人,Clcr,0,25.00,mL/min,mL/min,嚴重腎功能不全者不建議使用,,201804261426,201804261426
IDIPH,成人,Clcr,0,10.00,mL/min,mL/min,給藥間隔 12-18 小時,,201804242359,201804242359
IDIPH,成人,Clcr,10.00,50.00,mL/min,mL/min,給藥間隔 6-12 小時,,201804242359,
IDIPH,成人,Clcr,50.00,0,mL/min,mL/min,給藥間隔 6 小時,,201804242358,
IDOR,成人,Clcr,0,10.00,mL/min,mL/min,Decrease dose by 50%,,201804191531,201804191531
IDYN,成人,Clcr,0,30.00,mL/min,mL/min,應從最低劑量開始使用，並密切監測病人腎功能,,201804141610,
IEND,成人,eGFR,0,10.00,mL/min/1.73m2,mL/min/1.73m2,降低50% 的劑量。,,201804301558,
IENH,成人,Clcr,0,29.99,mL/min,mL/min,No recommendation was established.,仿單 20230116,202301161546,202301161546
IEPH,成人,Clcr,0,0,mL/min,mL/min,老年病人會建議從一般建議劑量之範圍中的最低劑量來開始使用,,201804120027,201804120027
IESM,成人,Clcr,0,0,mL/min,mL/min,使用 0.6 mg.kg-1 之 rocuronium bromide為快速麻醉誘導之插管劑量時，這類病人之臨床作用時間預期可能會延長。無論使用何種麻醉技術，這類病人之推薦維持劑量為0.075-0.1 mg.kg-1之rocuronium bromide，而推薦輸注率為0.3~0.4 mg.kg-1.h-1,,201804160518,
IFADI,成人,Clcr,49.00,0,mL/min,mL/min,Administer 50% of dose or increase the dosing interval to every 36 to 48 hours.,uptodate 20200803,202003121413,202008031022
IFAM,成人,Clcr,0,49.99,mL/min,mL/min,Administer 50% of dose or increase the dosing interval to every 36 to 48 hours.,,201804131612,201910141634
IFAS,成人,Clcr,0,30.00,mL/min,mL/min,須謹慎使用,,201805021609,
IFAS0,成人,Clcr,0,30.00,mL/min,mL/min,須謹慎使用,,201805021609,
IFIR,成人,eGFR,0,49.99,mL/min/1.73m2,mL/min/1.73m2,use with caution.,,201902271525,
IFIR8,成人,eGFR,0,49.99,mL/min/1.73m2,mL/min/1.73m2,use with caution.,,201812191213,
IFMR,成人,Clcr,5.00,0,mL/min,mL/min,0.5g/day,2021/01/28廠商提供資訊,202101281551,202101281542
IFMR,成人,Clcr,25.00,5.00,mL/min,mL/min,1g/day,2021/01/28廠商提供資訊,202101281542,202101281542
IFMR,成人,Clcr,50.00,25.00,mL/min,mL/min,2g/day,2021/01/28廠商提供資訊,202101281541,202101281542
IFMR,成人,Clcr,60.00,0,mL/min,mL/min,無相關紀載,仿單,202101251230,
IFOLI,成人,Clcr,0,0,mL/min,mL/min,病人若有腹水，胸膜滲透液，腎功能障礙或Hydration不夠時會延遲methotrexate排出，應考慮增加Folina劑量或延長治療時間,,201804191521,201804191521
IFRA,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer's labeling. Use with caution in severe renal impairment; accumulation may occur with repeated dosing， increasing the risk for bleeding.,,201804191146,
IFRA5,成人,Clcr,30.00,0,mL/min,mL/min,對於顯著腎衰竭之病人(其定義為肌酸酐>3倍ULN)，應調整dalteparin的劑量， 使抗Xa因子濃度在注射dalteparin後4~6小時維持在1 IU/mL (範圍：0.5-1.5 IU/mL)的治療 濃度。如果抗Xa因子濃度低於或高於治療範圍，應分別用注射針筒製劑增加或降低劑量， 並於投予3-4個新劑量之後重新檢測抗Xa因子濃度。重複進行此種劑量調整，直至達到 抗Xa因子治療濃度為止。,仿單,202110061300,202110061301
IFUR1,成人,Clcr,0,0,mL/min,mL/min,a supplemental dose should be given after hemodialysis,血液透析患者,201803261645,
IFUR1,成人,Clcr,0,9.99,mL/min,mL/min,750 mg every 24 hr,,201803261645,
IFUR1,成人,Clcr,10.00,20.00,mL/min,mL/min,750 mg every 12 hr,,201803261644,
IFYT,成人,Clcr,15.00,50.00,mL/min,mL/min,75%劑量,,201805021612,201805021612
IFYT,成人,Clcr,50.00,120.00,mL/min,mL/min,100%劑量,,201805021612,201805021612
IGEN8,成人,Clcr,20.00,39.00,mL/min,mL/min,usual mg/kg dose every 48 hours (once-daily dosing),,202003150919,
IGEN8,成人,Clcr,40.00,59.00,mL/min,mL/min,usual mg/kg dose every 36 hours (once-daily dosing),,202003150919,
IGEN8,成人,Clcr,60.00,120.00,mL/min,mL/min,usual mg/kg dose every 24 hours (once-daily dosing),,202003150919,
IGENT,成人,Clcr,20.00,39.00,mL/min,mL/min,usual mg/kg dose every 48 hours (once-daily dosing),,,
IGENT,成人,Clcr,40.00,59.00,mL/min,mL/min,usual mg/kg dose every 36 hours (once-daily dosing),,,
IGENT,成人,Clcr,60.00,120.00,mL/min,mL/min,usual mg/kg dose every 24 hours (once-daily dosing),,,
IGLY1,成人,Clcr,0,0,mL/min,mL/min,腎功能障礙之病患應謹慎使用,仿單,201804121422,202201120909
IGLY3,成人,Clcr,0,0,mL/min,mL/min,腎功能障礙之病患應謹慎使用,仿單,202201120909,202201120909
IHALA,成人,Clcr,15.00,49.00,mL/min,mL/min,Reduce initial dose to 1.1 mg/m2,202106仿單,202106171505,202106171519
IHYC,成人,Clcr,20.00,39.00,mL/min,mL/min,0.75mg/m2,,201805021619,
IHYC,成人,Clcr,40.00,60.00,mL/min,mL/min,不需調整,,201805021619,
IIG3,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,IV: Use with caution due to risk of immune globulin-induced renal dysfunction; the rate of infusion and concentration of solution should be minimized. Discontinue if renal function deteriorates during treatment.,,201804231623,
IINV2,成人,Clcr,0,50.00,mL/min,mL/min,不建議使用,,201804142336,201804142336
IINV2,成人,Clcr,50.00,80.00,mL/min,mL/min,156 mg IM on day 1 and 117 mg IM 1 week later,maintenance， 78 mg IM monthly,201804142336,
IINVZ,成人,Clcr,0,0,mL/min,mL/min,Hemodialysis: 500 mg IV every 24 hours; supplemental dose of 150 mg after hemodialysis if last dose administered within 6 hours prior to hemodialysis,Micromedex 20211005,202110051935,202110051934
IINVZ,成人,Clcr,30.00,0,mL/min,mL/min,CrCl 30 mL/min or less， 500 mg IV every 24 hours,Micromedex 20211005,202110051934,202110051934
IKCL,成人,Clcr,0,0,mL/min,mL/min,嚴重腎臟疾病，Addison氏症，高血鉀症不建議使用,,201804261451,
IKCL2,成人,Clcr,0,0,mL/min,mL/min,嚴重腎臟疾病，Addison氏症，高血鉀症不建議使用,,201804261452,201804261452
IKCL5S,成人,Clcr,0,0,mL/min,mL/min,嚴重腎臟疾病，Addison氏症，高血鉀症不建議使用,,201804261453,201804261453
IKCL6,成人,Clcr,0,0,mL/min,mL/min,嚴重腎臟疾病，Addison氏症，高血鉀症不建議使用,,201804261455,201804261455
IKCL7S,成人,Clcr,0,0,mL/min,mL/min,嚴重腎臟疾病，Addison氏症，高血鉀症不建議使用,,201804261456,201804261456
IKCL8S,成人,Clcr,0,0,mL/min,mL/min,嚴重腎臟疾病，Addison氏症，高血鉀症不建議使用,,201804261456,201804261456
IKEP,成人,Clcr,0,30.00,mL/min,mL/min,250 to 500 mg IV every 12 hours,,201804160412,201804160416
IKEP,成人,Clcr,30.00,50.00,mL/min,mL/min,250 to 750 mg IV every 12 hours,,201804160412,
IKEP,成人,Clcr,50.00,80.00,mL/min,mL/min,500 to 1000 mg IV every 12 hours,,201804160411,
IKETO,成人,Clcr,0,30.00,mL/min,mL/min,腎功能不全者，建議給藥間隔為 每6小時 每次15mg,最高每日劑量為60 mg/day,201804141541,201912091116
ILEV,成人,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,老年病人會建議從一般建議劑量之範圍中的最低劑量來開始使用,,201808231126,
ILEV2,成人,Clcr,0,0,mL/min,mL/min,老年病人會建議從一般建議劑量之範圍中的最低劑量來開始使用,,201804120029,201804120029
ILEVET,成人,Clcr,0,30.00,mL/min,mL/min,250 to 500 mg IVD every 12 hours,,201903240936,201903241015
ILEVET,成人,Clcr,0,0,mL/min,mL/min,End-stage renal disease (ESRD) requiring hemodialysis: 500 to 1000 mg IVD QD (治療首日建議劑量為750 mg，洗腎後建議補充劑量為250至500 mg),,201903241015,201903241022
ILEVET,成人,Clcr,30.00,50.00,mL/min,mL/min,250 to 750 mg IVD every 12 hours,,201903240936,201903241015
ILEVET,成人,Clcr,50.00,80.00,mL/min,mL/min,500 to 1000 mg IVD every 12 hours,,201903240936,201903241015
ILFT,成人,Clcr,0,4.99,mL/min,mL/min,Loading dose 1-2g， followed by 0.5-1g Q24-48H,UpToDate 2023-01-12,202301121140,202301121139
ILFT,成人,Clcr,0,9.99,mL/min,mL/min,2 gm q24-48h,Sanford Guide 2023-01-15,202301150907,202301121148
ILFT,成人,Clcr,0,0,mL/min,mL/min,Loading dose 1-2 g after each hemodialysis; maintenance dose as noted above based on ClCr,Hemodialysis. UpToDate 2023-01-12,202301121148,202301121148
ILFT,成人,Clcr,0,0.01,mL/min,mL/min,2 gm q24h-48h; extra 1 gm after hemodialysis,Hemodialysis. Sanford Guide 2023-01-15,202301150911,202301121148
ILFT,成人,Clcr,5.00,9.00,mL/min,mL/min,Loading dose 1-2g， followed by 0.5-1g Q12-24H,UpToDate 2023-01-12,202301121140,202301121139
ILFT,成人,Clcr,10.00,29.00,mL/min,mL/min,Loading dose 1-2g， followed by 1-2g Q12-24H,UpToDate 2023-01-12,202301121139,202301121139
ILFT,成人,Clcr,10.00,50.00,mL/min,mL/min,2 gm q8-12h,Sanford Guide 2023-01-15,202301150907,202301150909
ILFT,成人,Clcr,30.00,50.00,mL/min,mL/min,Loading dose 1-2g， followed by 1-2g Q8-12H,UpToDate 2023-01-12,202301121138,202301121138
ILIG2,成人,Clcr,0,30.00,mL/min,mL/min,Administer maintenance infusion at lower rate with close monitoring,Micromedex 20210217,202102171142,202102171143
ILIP20,成人,Clcr,0,0,mL/min,mL/min,未接受透析治療之嚴重腎功能不全者不建議使用,,201804261436,201804261436
IMAG2,成人,Clcr,0,0,mL/min,mL/min,有腎功能障礙之患者，高鎂血症患者必須審慎投與,,201804261459,201804261459
IMAN1,成人,Clcr,0,0,mL/min,mL/min,嚴重腎臟疾病或進行性腎損害或腎功能障礙之完全無尿病患不建議使用,,201804121420,
IMAR4,成人,Clcr,0,0,mL/min,mL/min,嚴重腎功能不全病患應小心使用，以減低發生危險副作用的風險,,201804191601,201804191601
IMARS,成人,Clcr,0,0,mL/min,mL/min,嚴重腎功能不全患者應小心使用，以減低發生危險副作用的風險,,201804191602,201804191602
IMAXI,成人,Clcr,0,0,mL/min,mL/min,輕至中度泌尿道感染(UTI):0.5g Q24h;輕至中度非泌尿道感染:0.5g Q24h;嚴重感染:0.5g Q24h;非常嚴重或有生命威脅之感染:0.5g Q24h,血液透析患者,201803261647,
IMAXI,成人,Clcr,0,10.00,mL/min,mL/min,輕至中度泌尿道感染(UTI):0.25g Q24h;輕至中度非泌尿道感染:0.25g Q24h;嚴重感染:0.5g Q24h;非常嚴重或有生命威脅之感染:1g Q24h,,201803261647,
IMAXI,成人,Clcr,11.00,29.00,mL/min,mL/min,輕至中度泌尿道感染(UTI):0.5g Q24h;輕至中度非泌尿道感染:0.5g Q24h;嚴重感染:1g Q24h;非常嚴重或有生命威脅之感染:2g Q24h,,201803261647,
IMAXI,成人,Clcr,30.00,50.00,mL/min,mL/min,輕至中度泌尿道感染(UTI):0.5g Q24h;輕至中度非泌尿道感染:1g Q24h;嚴重感染:2g Q24h;非常嚴重或有生命威脅之感染:2g Q12h,,201803261646,
IMAXI,成人,Clcr,50.00,199.00,mL/min,mL/min,輕至中度泌尿道感染(UTI):0.5g Q12h;輕至中度非泌尿道感染:1g Q12h;嚴重感染:2g Q12h;非常嚴重或有生命威脅之感染:2g Q8h,,201803261646,
IMEP2,成人,Clcr,0,10.00,mL/min,mL/min,劑量減半，每24小時投予一次,1gm/day,,
IMEP2,成人,Clcr,10.00,25.00,mL/min,mL/min,劑量減半，每12小時投予一次,1gm/day,,
IMEP2,成人,Clcr,26.00,50.00,mL/min,mL/min,一般劑量，每12小時投予一次,2gm/day,,
IMORP,成人,eGFR,0,10.00,mL/min/1.73m2,mL/min/1.73m2,Reduce dose by 50% or consider alternative opioid analgesics,,201804141507,201804141508
IMORP,成人,eGFR,10.00,50.00,mL/min/1.73m2,mL/min/1.73m2,Reduce dose by 25%,,201804141507,
IMTX2,成人,Clcr,0,15.00,mL/min,mL/min,嚴重腎功能不全禁用,,201804301634,
IMUT,成人,Clcr,50.00,0,mL/min,mL/min,本藥經由腎臟排泄，腎功能障礙患者請小心並減量使用,仿單,202104061013,
IMV13,成人,eGFR,0,59.99,mL/min/1.73m2,mL/min/1.73m2,腎功能障礙者謹慎使用。,,201804231722,
INEP,成人,Clcr,0,0,mL/min,mL/min,若引起腎功能低下，則須先補充足量水分及電解質,,201804261430,
INOB,成人,Clcr,0,30.00,mL/min,mL/min,250 to 500 mg IV every 12 hours,,201804141516,201804141516
INOB,成人,Clcr,30.00,50.00,mL/min,mL/min,250 to 750 mg IV every 12 hours,,201804141514,201804141515
INOB,成人,Clcr,50.00,80.00,mL/min,mL/min,500 to 1000 mg IV every 12 hours,,201804141514,
IOLA5,成人,Clcr,0,30.00,mL/min,mL/min,禁忌,,201804301602,
IOLI3,成人,Clcr,0,0,mL/min,mL/min,腎功能不全的患者應謹慎使用,,201804261523,201804261523
IOPT,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer’s labeling. Use caution in severe impairment， anuria， and in setting of combined renal and hepatic disease.,,201804181143,
IORE,成人,Clcr,0,29.90,mL/min,mL/min,藥品仿單：禁忌使用在ClCr<30 mL/min的患者。 UPTODATE：Reduce dose from 85 mg/m2 to 65 mg/m2.,,201803221503,201811081514
IPAM2,成人,Clcr,0,0,mL/min,mL/min,腎功能不全者劑量應該減低,,201804191507,201804191507
IPAR,成人,Clcr,15.00,150.00,mL/min,mL/min,總劑量(mg) = ( 目標AUC) x (GFR+25),,201804301604,
IPAR,成人,Clcr,16.00,40.00,mL/min,mL/min,200 mg/m2,202106仿單,202106171700,
IPAR,成人,Clcr,41.00,59.00,mL/min,mL/min,250 mg/m2,202106仿單,202106171701,202106171701
IPCN3,成人,eGFR,0.01,9.99,mL/min,mL/min,Administer 20% to 50% of the normal dose,(Aronoff 2007),202004021527,202004021523
IPCN3,成人,eGFR,10.00,50.00,mL/min,mL/min,Administer 75% of the normal dose,(Aronoff 2007),202004021528,202004021523
IPCN3,成人,Clcr,0.01,9.99,mL/min/1.73 m^2,mL/min/1.73 m^2,administer full loading dose， followed by 50% loading dose every 8 to 10 hours,Manufacturer's labeling,201803051606,202004021523
IPCN3,成人,Clcr,10.00,130.00,mL/min/1.73 m^2,mL/min/1.73 m^2,administer a full loading dose， followed by 50% loading dose every 4 to 5 hours,Manufacturer's labeling,201803051608,202004021523
IPEGA,成人,Clcr,0,29.99,mL/min,mL/min,Reduce to 135 mcg/wk; if severe adverse reactions develop， reduce to 90 mcg/wk; if intolerance persists， discontinue therapy.,血液透析病人:Reduce to 135 mcg/wk; if severe adverse reactions develop， reduce to 90 mcg/wk; if intolerance persists， discontinue therapy.,,
IPERD,成人,Clcr,0,0,mL/min,mL/min,Titrate infusion gradually,,201804121507,201804121507
IPET,成人,Clcr,0,10.00,mL/min,mL/min,Reduce initial dose ，give 50% of the normal dose at the usual intervals,,201804141520,
IPET,成人,Clcr,10.00,50.00,mL/min,mL/min,Give 75% of the normal dose at the usual intervals,,201804141519,
IPEY,兒童,eGFR,0,999.99,mL/min/1.73m2,mL/min/1.73m2,use with caution. (has not been studied),,201812091137,201812091137
IPHE,成人,Clcr,0,30.00,mL/min,mL/min,Reduce dose. Severe: Contraindicated.,,201809041537,
IPRI,成人,Clcr,0,40.00,mL/min,mL/min,Initiate at 50% of usual dosage  最大劑量為單一劑量每公斤體重0.2毫克(0.2mg/kg/dose)。,每日總劑量不可超過每公斤體重0.5毫克。,201804141427,201804141427
IPRIM,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,嚴重腎功能受損的病患，因顯影劑的排除較慢，應權衡利弊得失後再使用本品,當再次使用於腎功能受損病患前需確認有足夠的時間排除體內的顯影劑,201804212357,201804212359
IPUL,成人,Clcr,0,10.00,mL/min,mL/min,CrCl < or =10 mL/minute and Hemodialysis， intermittent (thrice weekly):33% (or less) of usual total daily dose.,UpToDate 20221219,202212191609,202212200902
IPUL,成人,Clcr,10.00,60.00,mL/min,mL/min,50% of usual total daily dose.,UpToDate 20221219,202212191608,202212191609
IRAPI,成人,Clcr,0,9.99,mL/min,mL/min,ESRD requiring intermittent hemodialysis (IHD): 50 mg as a single dose， administered after dialysis,,201812110943,201812110946
IRAPI,成人,Clcr,10.00,29.99,mL/min,mL/min,50 mg as a single dose,,201812110943,201812110945
IRAPI,成人,Clcr,30.00,49.99,mL/min,mL/min,100 mg as a single dose,,201812110942,201812110945
IRIN4,成人,Clcr,0,0,mL/min,mL/min,腎機能不全者應謹慎投與,,201804231404,201804231404
IRIS,成人,Clcr,0,0,mL/min,mL/min,建議起始劑量是第一週每日服用risperidone 0.5 mg 兩次，第二週則增加為每日口服1 mg 兩次或每日服用2 mg 一次。若病人對每日服用至少2 mg 的耐受度佳，即可每兩週注射RISPERDAL CONSTAR 25 mg,,201804142343,
IROP,成人,Clcr,0,0,mL/min,mL/min,腎功能不全者通常不需要調整劑量,但慢性腎衰竭病人常伴有酸中毒或血漿蛋白減少，其發生全身性毒性作用之危險性較高,201804191557,201804191557
ISEF,成人,Clcr,0,30.00,mL/min,mL/min,靜脈注射每日最大劑量為一天400毫克,仿單,202201061542,
ISEF,成人,Clcr,5.00,29.00,mL/min,mL/min,200 to 400 mg IV every 18 to 24 hours; alternatively， may give 400 mg every 24 hours for CrCl less than 30 mL/min/1.73 m(2).,Micromedexs 20220106,202201061554,202201061556
ISEF,成人,Clcr,31.00,60.00,mL/min,mL/min,靜脈注射每日最大劑量為一天800毫克,仿單,202201061542,
ISEV,成人,Clcr,0,14.99,mL/min,mL/min,不建議使用,,,
ISEV,成人,Clcr,15.00,25.00,mL/min,mL/min,以標準劑量為最大劑量，給藥三天後劑量減半,,,
ISIMD,成人,Clcr,0,30.00,mL/min,mL/min,Contraindication. Avoid use.,,201809101151,
ISIMD,成人,Clcr,30.10,50.00,mL/min,mL/min,Simdax must be used with caution in patients with mild to moderate renal impairment.,,201809101152,201809101152
ISOBI,成人,Clcr,0,0,mL/min,mL/min,腎功能障礙的患者應謹慎投與,,201804261507,201804261507
ISOLM,成人,Clcr,0,0,mL/min,mL/min,腎功能不全患者應謹慎使用,,201804231408,201804231408
ISOO,成人,Clcr,0,0.01,mL/min,mL/min,Patients on hemodialysis should receive a maintenance dose of 250 or 500 mg amoxicillin/125 mg clavulanic acid every 24 hours， with a supplemental dose given both during and at the end of dialysis,Micromedex 20210318,202103181208,202103181206
ISOO,成人,Clcr,0.10,9.99,mL/min,mL/min,先靜脈注射1劑1.2gm，然後再每24小時0.6gm. 洗腎後可能必須額外增加1劑0.6gm.,仿單,202103181144,202103181210
ISOO,成人,Clcr,0.10,10.00,mL/min,mL/min,The suggested dose is 250 or 500 mg amoxicillin/125 mg clavulanic acid every 24 hours.,Micromedex 20210318,201803051616,202103181210
ISOO,成人,Clcr,10.00,30.00,mL/min,mL/min,The suggested dose is 250 mg to 500 mg amoxicillin/125 mg clavulanic acid every 12 hours.,Micromedex 20210318,201803051616,202103181205
ISOO,成人,Clcr,10.00,29.99,mL/min,mL/min,先靜脈注射1劑1.2gm，然後再每12小時0.6gm.,仿單,202103181142,202103181146
ISOO,成人,Clcr,30.00,60.00,mL/min,mL/min,無須改變劑量,仿單,202103181140,
ISTO,成人,Clcr,0,0.01,mL/min,mL/min,循環中Cimetidine濃度會因血液透析而降低，因此本品須於透析最後階段給藥。,仿單,202012031652,202012031655
ISTO,成人,Clcr,0,15.00,mL/min,mL/min,每日二次，每次投與 200 毫克,仿單,202012031653,
ISTO,成人,Clcr,15.00,30.00,mL/min,mL/min,每日三次，每次 200 毫克,仿單,202012031654,
ISTO,成人,Clcr,30.00,50.00,mL/min,mL/min,每日四次，每次 200 毫克,仿單,202012031655,
ISUB,成人,Clcr,5.00,14.00,mL/min,mL/min,1.5-3g every 24 hours,,201803261539,
ISUB,成人,Clcr,15.00,29.00,mL/min,mL/min,1.5-3g every 12 hours,,201803261538,
ISUB,成人,Clcr,30.00,199.00,mL/min,mL/min,1.5-3g every 6 to 8 hours,,201803261538,201803261603
ITAP,成人,Clcr,0,0,mL/min,mL/min,2.25g every 12 hours plus 0.75 g after each dialysis session ;院內感染性肺炎2.25g every 8 hours plus 0.75 g after each dialysis session,血液透析患者,201803261550,
ITAP,成人,Clcr,0,20.00,mL/min,mL/min,2.25g every 8 hours;院內感染性肺炎2.25g every 6 hours,,201803261549,
ITAP,成人,Clcr,20.00,40.00,mL/min,mL/min,2.25g every 6 hours; 院內感染性肺炎3.375g every 6 hours,,201803261544,
ITAR,成人,Clcr,0,40.00,mL/min,mL/min,(含血液透析病人)治療第四天起每日給予三分之一的維持劑量，或每三日給予起始劑量，或每日給予三分之一的起始劑量,4mg/kg/day,,
ITAR,成人,Clcr,40.00,60.00,mL/min,mL/min,治療第四天起可每日給予減半的維持劑量，或每兩日給予起始劑量，或每日給予減半的起始劑量,6mg/kg/day,,
ITHYR,成人,Clcr,0,0,mL/min,mL/min,倚賴透析的末期腎臟病病人排泄 Thyrogen的速度非常慢，因此會延長提高 TSH 濃度的作用，須謹慎觀察。,,201804112350,201804112350
ITIE5,成人,Clcr,0,5.00,mL/min,mL/min,若同時接受血液透析者，可用ClCr=6~20min/mL的建議劑量，給藥時間分別為透析後與12小時後,500mg Q12H,,
ITIE5,成人,Clcr,6.00,20.00,mL/min,mL/min,250mg Q12H(原1gm/day， 1.5gm/day， 2gm/day)， 500mg Q12H(原3gm/day， 4gm/day),500mg Q12H,,
ITIE5,成人,Clcr,21.00,40.00,mL/min,mL/min,250mg Q12H(原1gm/day)， 250mg Q8H(原1.5gm/day)， 250mg Q6H(原2gm/day)， 500mg Q8H(原3gm/day)， 500mg Q6H(原4gm/day),500mg Q6H,,
ITIE5,成人,Clcr,41.00,70.00,mL/min,mL/min,250mg Q8H(原1gm/day)， 250mg Q6H(原1.5gm/day)， 500mg Q8H(原2gm/day)， 500mg Q6H(原3gm/day)， 750mg Q8H(原4gm/day),750mg Q8H,,
ITIEN,成人,Clcr,0,5.00,mL/min,mL/min,若同時接受血液透析者，可用ClCr=6~20min/mL的建議劑量，給藥時間分別為透析後與12小時後,500mg Q12H,201907111034,
ITIEN,成人,Clcr,6.00,20.00,mL/min,mL/min,250mg Q12H(原1gm/day， 1.5gm/day， 2gm/day)， 500mg Q12H(原3gm/day， 4gm/day),500mg Q12H,201907111034,
ITIEN,成人,Clcr,21.00,40.00,mL/min,mL/min,250mg Q12H(原1gm/day)， 250mg Q8H(原1.5gm/day)， 250mg Q6H(原2gm/day)， 500mg Q8H(原3gm/day)， 500mg Q6H(原4gm/day),500mg Q6H,201907111034,
ITIEN,成人,Clcr,41.00,70.00,mL/min,mL/min,250mg Q8H(原1gm/day)， 250mg Q6H(原1.5gm/day)， 500mg Q8H(原2gm/day)， 500mg Q6H(原3gm/day)， 750mg Q8H(原4gm/day),750mg Q8H,201907111034,
ITPN1,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Use with caution in patients with renal impairment; dosage adjustment may be necessary. Some products are contraindicated in patients with severe renal failure.,,201804261532,201804261532
ITPN1A,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Use with caution in patients with renal impairment; dosage adjustment may be necessary. Some products are contraindicated in patients with severe renal failure.,,201804261527,201804261528
ITPN2,成人,eGFR,0,59.00,mL/min/1.73m2,mL/min/1.73m2,Use with caution in patients with renal impairment; dosage adjustment may be necessary. Some products are contraindicated in patients with severe renal failure.,,201804261528,201804261528
ITPN2A,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Use with caution in patients with renal impairment; dosage adjustment may be necessary. Some products are contraindicated in patients with severe renal failure.,,201804261529,201804261529
ITPN3,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Use with caution in patients with renal impairment; dosage adjustment may be necessary. Some products are contraindicated in patients with severe renal failure.,,201804261529,201804261529
ITPNP1,兒童,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Use with caution in patients with renal impairment; dosage adjustment may be necessary. Some products are contraindicated in patients with severe renal failure.,,201804261531,201804261531
ITPNP2,兒童,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Use with caution in patients with renal impairment; dosage adjustment may be necessary. Some products are contraindicated in patients with severe renal failure.,,201804261531,201804261531
ITPNP3,兒童,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Use with caution in patients with renal impairment; dosage adjustment may be necessary. Some products are contraindicated in patients with severe renal failure.,,201804261532,201804261532
ITRAM,成人,Clcr,0,30.00,mL/min,mL/min,increase dosing interval to 12 hours,MAX 200 mg/day,201804141523,201804141523
ITRAN,成人,Scr,1.36,2.83,mg/dL,mg/dL,Maintenance dose of 10 mg/kg/dose twice daily,,201804231437,
ITRAN,成人,Scr,2.83,5.66,mg/dL,mg/dL,Maintenance dose of 10 mg/kg/dose once daily,,201804231438,
ITRAN,成人,Scr,5.66,99.00,mg/dL,mg/dL,Maintenance dose of 10 mg/kg/dose every 48 hours or 5 mg/kg/dose once daily,,201804231438,201804231439
IVAN1,成人,Clcr,0,0,mL/min,mL/min,Hemodialysis: Less than 70 kg， 1000-mg loading dose and then 500-mg maintenance dose infused over last 30 minutes of dialysis; 70 to 100 kg， 1250-mg loading dose and then 750-mg maintenance dose infused over last 60 minutes of dialysis; greater than 100 kg， 1500-mg loading dose and then 1000-mg maintenance dose infused over last 90 minutes of dialysis,Micromedex 20201123,202011231000,202011231001
IVAN1,成人,Clcr,60.00,0,mL/min,mL/min,Renal impairment (adult and pediatric): 15 mg/kg initially and then optimize dose and interval based on serum drug concentrations,Micromedex 20201123,202011230958,202011231001
IVAN1,成人,Clcr,100.00,0,mL/min,mL/min,劑量是每天mg之腎絲球過濾速率ml/min 的15倍，請依此參照100mL/min:1545mg/24hr; 90mL/min:1390mg/24hr; 80mL/min:1235mg/24hr; 70mL/min:1080mg/24hr; 60mL/min:925mg/24hr; 50mL/min:770mg/24hr; 40mL/min:620mg/24hr; 30mL/min:465mg/24hr; 20mL/min:310mg/24hr; 10mL/min:155mg/24hr;最初劑量不可少於15mg/kg，對中度至重度腎不全患者亦同。,仿單,202011230948,202011231001
IVANS,成人,eGFR,0,15.00,mL/min/1.73m2,mL/min/1.73m2,<60kg:750mg; 60-80kg:1000mg; 81-100kg:1250mg; >100kg:1500mg.Check a random vancomycin level in 24 hours after the dose. If random level is =<20 mcg/mL， repeat the dose. If random level is >20 mcg/mL， do not redose; repeat random level in 12 hours.,[UpToDate on 2020-05-07],202005071141,202005071142
IVANS,成人,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,End-stage renal disease on intermittent hemodialysis (administer after hemodialysis on dialysis days): Following loading dose of 15 to 25 mg/kg， give either 500 to 1，000 mg or 5 to 10 mg/kg after each dialysis session. Note: Dosing dependent on the assumption of 3 times/week， complete IHD sessions.,[UpToDate on 2020-05-07],202005071143,202005071145
IVANS,成人,eGFR,15.00,49.00,mL/min/1.73m2,mL/min/1.73m2,<60kg:750mg Q24H; 60-80kg:1000mg Q24H; 81-100kg:1250mg Q24H; >100kg:1500mg Q24H,[UpToDate on 2020-05-07],202005071138,
IVANS,成人,eGFR,50.00,90.00,mL/min/1.73m2,mL/min/1.73m2,<60kg:750mg Q12H; 60-80kg:1000mg Q12H; 81-100kg:1250mg Q12H; >100kg:1000mg Q8H,[UpToDate on 2020-05-07],202005071137,202005071140
IVANS,成人,eGFR,90.00,999.00,mL/min/1.73m2,mL/min/1.73m2,<60kg:750mg Q8H; 60-80kg:1000mg Q8H; 81-100kg:1250mg Q8H; >100kg:1500mg Q8H,[UpToDate on 2020-05-07],202005071134,202005071139
IVANS,成人,Clcr,0,10.00,mL/min,mL/min,7.5mg/kg Q2D-Q3D,[Sanford Guide - Antimicrobial on 2020-05-07],202005071202,202005071200
IVANS,成人,Clcr,0,0,mL/min,mL/min,7.5mg/kg Q2D-Q3D; at end of hemodialysis on dialysis days: next hemodialysis in 1 day: 15mg/kg; 2 day: 25mg/kg; 3days: 35mg/kg,[Sanford Guide - Antimicrobial on 2020-05-07],202005071208,202005071200
IVANS,成人,Clcr,10.00,100.00,mL/min,mL/min,每日劑量（mg）約為腎絲球濾過率（ml/min）的15倍(穩定狀況下的腎功能),[仿單],,202005071209
IVANS,成人,Clcr,10.00,50.00,mL/min,mL/min,15mg/kg Q24-96h,[Sanford Guide - Antimicrobial on 2020-05-07],202005071201,202005071200
IVANS,成人,Clcr,50.00,120.00,mL/min,mL/min,15mg/KG Q12H,[仿單],,202005071210
IVANS,成人,Clcr,50.00,90.00,mL/min,mL/min,15-30mg/kg Q12h,[Sanford Guide - Antimicrobial on 2020-05-07],202005071200,202005071200
IVC5,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,ESRD (requiring hemodialysis): Adults: IV， Oral: 60 to 100 mg once daily is sufficient to prevent serious ascorbate deficiency due to loss from dialysis; doses >100 mg daily may lead to secondary oxalosis and renal oxalate stone formation.,,201804231727,
IVEK,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,成人、嬰兒、兒童及較大兒童: 不建議使用。只有在潛在效益超越潛在風險的情況下才可考慮投予,仿單,202106091140,202301041112
IVEK,成人,eGFR,0,29.99,mL/min/1.73m2,mL/min/1.73m2,Use not recommended. Remdesivir pharmacokinetics have not been evaluated in patients with renal impairment; possible accumulation of the excipient betadex sulfobutyl ether sodium may occur in patients with decreased renal function.,Micromedex 20210609,202106091143,202301041111
IVEKS,成人,eGFR,0,29.99,mL/min/1.73m2,mL/min/1.73m2,Use not recommended. Remdesivir pharmacokinetics have not been evaluated in patients with renal impairment; possible accumulation of the excipient betadex sulfobutyl ether sodium may occur in patients with decreased renal function.,Micromedex 20210609,202301041111,
IVEKS,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,成人、嬰兒、兒童及較大兒童: 不建議使用。只有在潛在效益超越潛在風險的情況下才可考慮投予。,仿單,202301041111,
IVER,成人,Clcr,0,0,mL/min,mL/min,If repeated IV doses are necessary， give smaller doses and closely monitor PR interval and blood pressure,,201804121510,201804121510
IVFEN,成人,Clcr,0,49.99,mL/min,mL/min,會建議改成口服方式治療(口服不會受腎功能障礙影響),,,
IVIM,成人,Clcr,0,0,mL/min,mL/min,血液透析可有效清除血漿中的 Lacosamide。4 小時的血液透析治療後，應考慮補充最多 50%的劑量。,仿單,202008031608,202008031607
IVIM,成人,Clcr,0.01,0,mL/min,mL/min,Removed by hemodialysis; after 4-hour hemodialysis treatment， a supplemental dose of up to 50% should be considered.,UpToDate 20200803,202008031615,202008031611
IVIM,成人,Clcr,29.99,0,mL/min,mL/min,CrCl <30 mL/minute: Reduce dose to 75% of the maximum dose.,UpToDate 20200803,202008031610,202008031611
IVIM,成人,Clcr,30.00,0,mL/min,mL/min,CLCR低於30毫升/分鐘/1.73公尺2:建議減少最大劑量的25%。,仿單,201912121034,202008031607
IVIM,成人,Clcr,60.00,29.99,mL/min,mL/min,CrCl >=30 mL/minute: No dosage adjustment necessary.,UpToDate 20200803,202008031611,202008031613
IVIM,兒童,Clcr,30.00,0,mL/min,mL/min,CLCR低於30毫升/分鐘/1.73公尺2:建議減少最大劑量的25%。,仿單,202008031605,202008031609
IVOR,成人,Clcr,0,30.00,mL/min,mL/min,Moderate to severe impairment: Use is not recommended; contraindicated in patients in the perioperative period and who are at risk for volume depletion.,,201912091140,201912091140
IXOL,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer’s labeling.,,201804191020,
IXOL0,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer’s labeling.,,201804191019,
IXYL2V,成人,Clcr,0,0,mL/min,mL/min,嚴重腎功能患者會因代謝遲緩而引起血漿中濃度上升，故謹慎使用之,,201804191548,201804191548
IZOV,成人,Clcr,0,9.99,mL/min,mL/min,50%正常劑量，給藥間隔24小時,,,
IZOV,成人,Clcr,0,0,mL/min,mL/min,血液透析病人:an additional dose is recommended after each dialysis,,,
IZOV,成人,Clcr,10.00,25.00,mL/min,mL/min,正常劑量，給藥間隔24小時,,,
IZOV,成人,Clcr,26.00,50.00,mL/min,mL/min,正常劑量，給藥間隔12小時,,,
LAMO5,兒童,eGFR,0,10.00,mL/min/1.73m2,mL/min/1.73m2,Mild to moderate infection(based on 25-50mg/kg/day，Q8H): 8-20mg/kg/dose，Q24H. Severe infection or high dose(based on 80-90mg/kg/day，Q12H): 20mg/kg/dose，Q24H; do not use the 875mg tablet.,Lexicomp(UpToDate). 2022/10/12,202210121531,202210121534
LAMO5,兒童,eGFR,10.00,29.00,mL/min/1.73m2,mL/min/1.73m2,Mild to moderate infection(based on 25-50mg/kg/day，Q8H): 8-20mg/kg/dose，Q12H. Severe infection or high dose(based on 80-90mg/kg/day，Q12H): 20mg/kg/dose，Q12H; do not use the 875mg tablet.,Lexicomp(UpToDate). 2022/10/12,202210121524,202210121534
LAMO6,成人,eGFR,0,0,mL/min,mL/min,250 to 500 mg every 24 hours; administer after dialysis on dialysis day,血液透析患者 (Aronoff 2007),201803261607,202004021622
LAMO6,成人,eGFR,0,10.00,mL/min,mL/min,GFR <10 mL/min: 250 to 500 mg every 24 hours,Lexi-Drugs. Lexicomp.,201803261606,202004021622
LAMO6,成人,eGFR,10.00,30.00,mL/min,mL/min,GFR 10-30 mL/min: 250 to 500 mg every 12 hours,Lexi-Drugs. Lexicomp.,201803261606,202004021622
LAUG3,兒童,eGFR,0.01,29.99,mL/min/1.73m2,mL/min/1.73m2,不建議使用,,201803261610,201803261610
LAZI,成人,eGFR,0,10.00,mL/min/1.73m2,mL/min/1.73m2,須謹慎使用,仿單,202210061458,202210131504
LAZI,成人,eGFR,10.00,80.00,mL/min/1.73m2,mL/min/1.73m2,無須調整劑量,仿單,202210061458,202210131504
LBIS,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer's labeling.,,201804191043,
LCAR,成人,Clcr,0,0,mL/min,mL/min,腎功能障礙及無尿排泄病人，半衰期可能延長至100小時，因此可能需要減少維持劑量。,,201804120035,201804120035
LCEF,成人,Clcr,0,10.00,mL/min,mL/min,creatinine clearance less than 10 mL/minute， 50% of the normal dose,Micromedex 20210105,202101051508,
LCEF,成人,Clcr,10.00,50.00,mL/min,mL/min,creatinine clearance 10 to 50 mL/minute， 50% to 100% of the normal dose,Micromedex 20210105,202101051507,
LCET,成人,eGFR,0,49.90,mL/min/1.73m2,mL/min/1.73m2,5 mg once daily,,201804231453,
LCET,成人,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,Intermittent hemodialysis: 5 mg once daily; 5 mg 3 times per week may also be effective.,,201804231454,
LCET,兒童,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,腎功能不全的患者服用本藥時，其劑量應減半,,201804250002,201804250002
LCLO,兒童,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,明顯腎功能損害者禁用,[仿單],202006161022,202006161022
LCOFS,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer's labeling.,,201804191045,
LFUL,成人,Scr,0,1.05,mg/dL,mg/dL,藥品仿單建議請勿使用於腎臟疾病的患者。,,201804021207,201804021206
LFUL,成人,eGFR,0,60.00,mL/min/1.73m2,mL/min/1.73m2,藥品仿單建議請勿使用於腎臟疾病的患者。,,201804021206,201804021206
LFUL,成人,Clcr,0,50.00,mL/min,mL/min,藥品仿單建議請勿使用於腎臟疾病的患者。,,201804021207,201804021206
LFUM,成人,eGFR,0,60.00,mL/min/1.73m2,mL/min/1.73m2,Acute renal failure: Doses up to 1 to 3 g daily may be necessary to initiate desired response; avoid use in oliguric states. Dialysis: Not removed by hemo- or peritoneal dialysis; supplemental dose is not necessary.,,201807261507,201807261509
LIDO1,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,Avoid use.(KDIGO 2012 guidelines),,201912091124,201912091123
LIDO1,成人,eGFR,30.00,60.00,mL/min/1.73m2,mL/min/1.73m2,Avoid use in patients with intercurrent disease that increases risk of acute kidney injury.(KDIGO 2012 guidelines),,201912091123,201912091123
LKEP,成人,Clcr,0,30.00,mL/min,mL/min,250 to 500 mg orally every 12 hours,,201804160418,201804160418
LKEP,成人,Clcr,30.00,50.00,mL/min,mL/min,250 to 750 mg orally every 12 hours,,201804160417,
LKEP,成人,Clcr,50.00,80.00,mL/min,mL/min,500 to 1000 mg orally every 12 hours,,201804160417,
LKID,成人,Clcr,0,0,mL/min,mL/min,腎功能不全患者應謹慎使用,,201804231416,201804231416
LMEP6,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer's labeling.,,201804191043,
LMUS2,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer's labeling.,,201804191015,
LPIR,成人,Clcr,0,20.00,mL/min,mL/min,禁用,,201804160611,201804160611
LPIR,成人,Clcr,20.00,30.00,mL/min,mL/min,正常劑量的1/6，每日一次服用,,201804160611,
LPIR,成人,Clcr,30.00,49.00,mL/min,mL/min,正常劑量的1/3，每日分兩次服用,,201804160611,
LPIR,成人,Clcr,50.00,79.00,mL/min,mL/min,正常劑量的2/3，每日分兩到三次服用,,201804160610,
LRIS,成人,Clcr,0,30.00,mL/min,mL/min,Initial， 0.5 mg orally twice daily; increase dose in increments of no more than 0.5 mg twice a day， with increases to dosages above 1.5 mg twice a day occurring at intervals of at least 1 week,,201804142348,201804142348
LSEC,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer's labeling.,,201804191047,
LSUL,成人,Clcr,0,14.99,mL/min,mL/min,不建議使用,,,
LSUL,成人,Clcr,15.00,30.00,mL/min,mL/min,one-half the usual dose,,,
LSUR,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer's labeling.,,201804191017,
LTRIL,成人,Clcr,0,30.00,mL/min,mL/min,治療劑量應為一般起始劑量應為一半(每天300mg)，再逐漸增加劑量以達到理想的臨床效果,,201804160419,201804160423
LULE,成人,Clcr,1.00,4.00,mL/min,mL/min,250mg every 48 or 60 hours,,201803261651,201803261650
LULE,成人,Clcr,5.00,14.00,mL/min,mL/min,250mg every 24 hours,,201803261650,201803261650
LULE,成人,Clcr,15.00,29.00,mL/min,mL/min,250mg every 8 or 12 hours,,201803261650,201803261650
LULE,成人,Clcr,30.00,59.00,mL/min,mL/min,不需調整,上限1g/day,201803261650,201803261650
LWEM,成人,Clcr,0,0,mL/min,mL/min,重度腎功能不全患者，建議依照腎功能受損程度調整給藥間隔為一天1~2次,,201804141441,201804141441
LZIT,成人,Clcr,0,9.00,mL/min,mL/min,應謹慎用藥,,,
LZIT,成人,Clcr,10.00,80.00,mL/min,mL/min,無須調整劑量,,,
OACAM,成人,Clcr,0,30.00,mL/min,mL/min,CrCl 30 mL/min or less， not recommended,,202002181022,
OACAM,成人,Clcr,30.00,50.00,mL/min,mL/min,CrCl between 30-50 mL/min， 333 mg ORALLY 3 times daily,,202002181022,
OACC6,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer's.,,201804191048,
OACE5,成人,Clcr,0,15.00,mL/min,mL/min,2.5 mg on the day of dialysis.,,201811291448,201811291447
OACE5,成人,Clcr,15.01,29.99,mL/min,mL/min,2.5 mg every other day.,,201804121556,201811291447
OACE5,成人,Clcr,30.00,60.00,mL/min,mL/min,2.5 mg per day.,,201804121557,201811291445
OACET,成人,eGFR,0,10.00,mL/min/1.73m2,mL/min/1.73m2,不建議使用,,201804121428,201804121428
OACET,成人,eGFR,10.00,50.00,mL/min/1.73m2,mL/min/1.73m2,increase dosing interval to every 12 hours,,201804121428,
OACET,成人,eGFR,50.00,0,mL/min/1.73m2,mL/min/1.73m2,increase dosing interval to every 6 hours,,201804121428,
OACH,成人,eGFR,10.00,0,mL/min/1.73m2,mL/min/1.73m2,Acetaminophen: Increase dosing interval to every 8 hours for adults and children,Micromedex20200923,202009230906,202009230908
OACH,成人,eGFR,50.00,10.00,mL/min/1.73m2,mL/min/1.73m2,Acetaminophen: Adult， increase dosing interval to every 6 hours,Micromedex20200923,202009230907,202009230908
OACH,兒童,eGFR,10.00,0,mL/min/1.73m2,mL/min/1.73m2,Acetaminophen: Increase dosing interval to every 8 hours for adults and children,Micromedex20200923,202009230906,202009230908
OACH,兒童,eGFR,50.00,10.00,mL/min/1.73m2,mL/min/1.73m2,Acetaminophen: pediatric， give usual weight- or age-based dose,Micromedex20200923,202009230907,202009230909
OAGT,成人,Clcr,0,30.00,mL/min,mL/min,禁止使用於重度腎功能不全病人。,仿單,202206271428,
OAGT,成人,Clcr,30.00,50.00,mL/min,mL/min,建議起始劑量為每日三次，每次服用一錠333毫克藥錠。,仿單,202206271427,
OAKY,成人,eGFR,1.00,0,mL/min/1.73m2,mL/min/1.73m2,Renal impairment， severe or ESRD: Avoid use,Micromedex 20201007,202010071059,
OALL6,成人,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,Intermittent hemodialysis or peritoneal dialysis: Recommended dose every 24 hours.,,201804231510,
OALL6,成人,eGFR,0,9.99,mL/min/1.73m2,mL/min/1.73m2,Recommended dose every 24 hours.,,201804231500,
OALL6,成人,eGFR,10.00,50.00,mL/min/1.73m2,mL/min/1.73m2,Recommended dose every 12 to 24 hours.,,201804231500,
OAMA,成人,Clcr,0,0,mL/min,mL/min,腎功能損傷者及血液透析患者，建議起始劑量為1mg/天,,201804111613,201804112332
OAMIZ,成人,Clcr,0,0,mL/min,mL/min,閉尿.急性腎衰竭.嚴重進行性腎病患不建議使用,,201804121432,201804121432
OAMO2,成人,eGFR,0,0,mL/min,mL/min,250 to 500 mg every 24 hours; administer after dialysis on dialysis day,血液透析患者 (Aronoff 2007),201803261626,202004021620
OAMO2,成人,eGFR,0.01,10.00,mL/min,mL/min,GFR <10 mL/min: 250 to 500 mg every 24 hours,Lexi-Drugs. Lexicomp,201803261626,202004021620
OAMO2,成人,eGFR,10.00,30.00,mL/min,mL/min,GFR 10-30 mL/min: 250 to 500 mg every 12 hours,Lexi-Drugs. Lexicomp,201803261625,202004021621
OAMO5,成人,eGFR,0,0,mL/min,mL/min,250 to 500 mg every 24 hours; administer after dialysis on dialysis day,血液透析患者 (Aronoff 2007),201803261626,202004021619
OAMO5,成人,eGFR,0.01,10.00,mL/min,mL/min,GFR 10-30 mL/min: 250 to 500 mg every 12 hours,Lexi-Drugs. Lexicomp.,201803261626,202004021618
OAMO5,成人,eGFR,10.00,30.00,mL/min,mL/min,GFR 10-30 mL/min: 250 to 500 mg every 12 hours,Lexi-Drugs. Lexicomp.,201803261625,202004021620
OAMOX,成人,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,250 mg or 500 mg every 24 hours， depending on severity of infection; give additional dose both during and at the end of dialysis,血液透析患者,202003200914,
OAMOX,成人,eGFR,0.01,10.00,mL/min/1.73m2,mL/min/1.73m2,250-500mg every 24 hours,,202003200914,
OAMOX,成人,eGFR,10.00,30.00,mL/min/1.73m2,mL/min/1.73m2,250-500mg every 12 hours,,202003200914,
OANS,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,不建議使用,,201804111625,201804111625
OAPA,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Hyperglycemia in patients with Cushing syndrome: Maximum dose: 600 mg once daily,,201806141726,
OAPR5,成人,Clcr,0,0,mL/min,mL/min,腎功能受損的病人，劑量需要減低,,201804121535,201804121536
OARC,成人,Clcr,0,30.00,mL/min,mL/min,不建議使用,,201804141616,
OARH1,成人,eGFR,0,59.99,mL/min/1.73m2,mL/min/1.73m2,Moderate to severe impairment: Use is contraindicated.,,201804231652,
OARIM,成人,Clcr,0,60.00,mL/min,mL/min,Renal impairment: No dosage adjustment necessary,Micromedex 20210504,202105040928,202105040931
OARIM,成人,Clcr,0,30.00,mL/min,mL/min,嚴重腎臟損傷病患(creatinine廓清率小於30)禁忌使用,仿單,202105040930,202105040925
OASP,成人,Clcr,0,9.90,mL/min,mL/min,The manufacturer recommends avoiding in patients with CrCl <10 mL/minute.,,201804191222,
OASV,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer's,,201804191049,
OAUG1,成人,Clcr,0,9.99,mL/min,mL/min,usual dose every 24 hours,,201803261630,
OAUG1,成人,Clcr,10.00,30.00,mL/min,mL/min,usual dose every 12 hours,,201803261629,
OAZI,成人,Clcr,0,9.00,mL/min,mL/min,應謹慎用藥,,202001221143,
OAZI,成人,Clcr,10.00,80.00,mL/min,mL/min,無須調整劑量,,202001221144,
OBAC5,成人,Clcr,0,30.00,mL/min,mL/min,Reduce dose by 2/3,,201804160522,201804160522
OBAC5,成人,Clcr,30.00,50.00,mL/min,mL/min,Reduce dose by 1/2,,201804160522,201804160522
OBAC5,成人,Clcr,50.00,80.00,mL/min,mL/min,Reduce dose by 1/3,,201804160521,
OBAR,成人,Clcr,10.00,0,mL/min,mL/min,Administer 10% of usual dose daily or administer the normal dose every 7 days; administer after hemodialysis,UpToDate,202004021451,202004021457
OBAR,成人,Clcr,29.00,10.00,mL/min,mL/min,Administer 30% of usual dose daily or administer the normal dose every 72 hours,UpToDate,202004021451,202004021457
OBAR,成人,Clcr,49.00,30.00,mL/min,mL/min,Administer 50% of usual dose daily or administer the normal dose every 48 hours,UpToDate,202004021452,202004021457
OBAR1,成人,Clcr,10.00,0,mL/min,mL/min,Administer 10% of usual dose daily or administer the normal dose every 7 days; administer after hemodialysis,UpToDate,202004021455,202004021457
OBAR1,成人,Clcr,29.00,10.00,mL/min,mL/min,Administer 30% of usual dose daily or administer the normal dose every 72 hours,UpToDate,202004021456,202004021457
OBAR1,成人,Clcr,49.00,30.00,mL/min,mL/min,Administer 50% of usual dose daily or administer the normal dose every 48 hours,UpToDate,202004021456,202004021457
OBECA,成人,Clcr,0,9.99,mL/min,mL/min,0.05 mg ORALLY once daily (preferred) or 0.5 mg ORALLY once every 7 days; lamivudine-refractory or decompensated liver disease， 0.1 mg ORALLY once daily (preferred) or 1 mg ORALLY once every 7 days.,,,
OBECA,成人,Clcr,0,0,mL/min,mL/min,血液透析病人:0.05 mg ORALLY once daily (preferred) or 0.5 mg ORALLY once every 7 days; lamivudine-refractory or decompensated liver disease， 0.1 mg ORALLY once daily (preferred) or 1 mg ORALLY once every 7 days; on hemodialysis days， administer after hemodialysis.,,,
OBECA,成人,Clcr,10.00,29.99,mL/min,mL/min,0.15 mg ORALLY once daily (preferred) or 0.5 mg ORALLY every 72 hours; lamivudine-refractory or decompensated liver disease， 0.3 mg ORALLY once daily (preferred) or 1 mg ORALLY once every 72 hours.,,,
OBECA,成人,Clcr,30.00,49.99,mL/min,mL/min,0.25 mg ORALLY once daily (preferred) or 0.5 mg ORALLY once every 48 hours; lamivudine-refractory or decompensated liver disease， 0.5 mg ORALLY once daily (preferred) or 1 mg ORALLY once every 48 hours.,,,
OBET2,成人,eGFR,15.00,29.00,mL/min/1.73m2,mL/min/1.73m2,重度腎功能不全病患每日劑量不可超過 25mg 一天一次,,201804212243,201804212243
OBET2,成人,Clcr,0,15.00,mL/min,mL/min,末期腎病的患者不建議使用,,201804212245,201804212245
OBET2,成人,Clcr,15.00,29.00,mL/min,mL/min,重度腎功能不全病患每日劑量不可超過 25mg 一天一次,,201804212243,
OBET5,成人,eGFR,0,15.00,mL/min/1.73m2,mL/min/1.73m2,不建議Betmiga使用於末期腎病的病人,仿單,202109271457,202109271456
OBET5,成人,eGFR,15.00,29.00,mL/min/1.73m2,mL/min/1.73m2,每日劑量不可超過25 mg一天一次。,仿單,202109271456,202109271456
OBET5,成人,Clcr,0,15.00,mL/min,mL/min,不建議Betmiga使用於末期腎病的病人,仿單,202109271455,202109271456
OBET5,成人,Clcr,15.00,29.00,mL/min,mL/min,每日劑量不可超過25 mg一天一次。,仿單,202109271455,
OBIN,成人,Clcr,0,35.00,mL/min,mL/min,不建議使用,,201804120000,201804120000
OBLO,成人,Clcr,0,15.00,mL/min,mL/min,對於重度或末期腎功能不全者(肌酸酐廓清率＜15mL/min)之臨床使用經驗有限。對於這些病患， 應該根據觀察血壓的監測小心逐次調整劑量。,仿單,202011130831,202011130834
OBLO,成人,Clcr,15.00,60.00,mL/min,mL/min,對於腎功能不全者，包括正在進行血液透析的患者，起始劑量為4mg，再根據患者反應逐次調整劑量。,仿單,202011130835,202011130834
OBOK,成人,Clcr,0,9.90,mL/min,mL/min,The manufacturer recommends avoiding in patients with CrCl <10 mL/minute.,,201804191223,
OBONE,成人,Clcr,0,30.00,mL/min,mL/min,每天800mg,,201804120002,201804120002
OBONE,成人,Clcr,30.00,50.00,mL/min,mL/min,每天1200mg,,201804120002,
OBONE,成人,Clcr,50.00,80.00,mL/min,mL/min,每天1600mg,,201804120001,
OBOW,成人,Clcr,0,30.00,mL/min,mL/min,腎功能嚴重下降患者不建議使用,,201804131641,201804131641
OBRO,成人,Clcr,0,0,mL/min,mL/min,重度腎功能不全者不建議使用,,201804191414,201804191414
OBUSR,成人,Clcr,0,0,mL/min,mL/min,腎功能不全且無尿患者建議Reduce dose by 25% to 50%,嚴重腎功能不全者不建議使用,201804150016,201804150017
OCAL5,成人,Clcr,0,24.99,mL/min,mL/min,Dosage adjustments may be necessary depending on the serum calcium levels.,,201804231741,201804231741
OCAN,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,Contraindications: severe renal impairment(eGFR <30 mL/minute/1.73 m2); end-stage renal disease or patients on dialysis.,仿單&Micromedex建議,201907091101,201907290914
OCAN,成人,eGFR,30.00,45.00,mL/min/1.73m2,mL/min/1.73m2,不建議使用,仿單建議,201907290913,201907091102
OCAND8,成人,Clcr,0,15.00,mL/min,mL/min,對於非常嚴重或者是末期的腎臟功能不良者 ( 肌酸酐廓清率Clcreatinine<15 mL/min)，臨床使用經驗有限,仿單,202011231047,202011130834
OCAND8,成人,Clcr,15.00,59.99,mL/min,mL/min,Renal impairment， adult (moderate to severe， CrCl 15 to 60 mL/min/1.73 m(2)): 8 mg daily may be a sufficient dose,Micromedex 20201123,202011231040,202011231048
OCAND8,成人,Clcr,15.00,60.00,mL/min,mL/min,對於腎功能不全者，包括正在進行血液透析的患者，起始劑量為4mg，再根據患者反應逐次調整劑量。,仿單,202011130850,202011130834
OCAND8,兒童,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,Renal impairment， pediatric (GFR less than 30 mL/min/1.73 m(2)): Use not recommended,Micromedex 20201123,202011231140,202011231048
OCAP5,成人,Clcr,0,29.90,mL/min,mL/min,Use is contraindicated.,,201803191622,
OCAP5,成人,Clcr,30.00,50.00,mL/min,mL/min,Reduce dose to 75% of usual dose,,201803191621,
OCAT,成人,Clcr,0,0,mL/min,mL/min,腎功能不全病人依病患降壓反應調整劑量，需小心監策測,,201804130627,201804130627
OCAT2,成人,Clcr,0,30.00,mL/min,mL/min,Significant impairment or advanced renal disease: Use is not recommended.,,201912091133,201912091133
OCEFA,成人,Clcr,0,9.99,mL/min,mL/min,Initial: 1g as single dose; maintenance: 500mg Q36H,Ref: Lexicomp Accessed: 2020-05-03,,202005030956
OCEFA,成人,Clcr,0,0,mL/min,mL/min,Hemodialysis: 1g then 1g AD CAPD: 500 mg q24h CRRT: No data,Ref: Sanford Guide Web Ed. Accessed: 2020-05-03,,202005030959
OCEFA,成人,Clcr,10.00,24.99,mL/min,mL/min,Initial: 1g as single dose; maintenance: 500mg QD,Ref: Lexicomp Accessed: 2020-05-03,,202005030955
OCEFA,成人,Clcr,25.00,49.99,mL/min,mL/min,Initial: 1g as single dose; maintenance: 500mg Q12H,Ref: Lexicomp Accessed: 2020-05-03,,202005030955
OCEL2,成人,Clcr,0,0,mL/min,mL/min,嚴重腎功能障礙病患不建議使用,,201804141619,201804141619
OCEPH,成人,Clcr,5.00,14.00,mL/min,mL/min,250mg every 24 hours,,,
OCEPH,成人,Clcr,15.00,29.00,mL/min,mL/min,250mg every 8 or 12 hours,,,
OCEPH,成人,Clcr,30.00,59.00,mL/min,mL/min,無須調整劑量,1g/day,,
OCEPO,成人,Clcr,0,0,mL/min,mL/min,藥物代謝會減低，在達到預期之治療效果後，服藥間隔宜加大或劑量宜減低,若同時須使用利尿劑建議loop diuretic，而非thiazide-type diuretic,201804121544,
OCER4,成人,Clcr,0,30.00,mL/min,mL/min,Reduce the dosage to 400 mg orally once daily,,201804130653,201804130703
OCEX,成人,eGFR,0,20.00,mL/min/1.73m2,mL/min/1.73m2,Reduce dose by 50%,Severe impairment & Anuric(eg， GFR <10 to 20 mL/minute/1.73 m2): Reduce dose by 50%,201909031537,201909031541
OCHA1,成人,Clcr,0,30.00,mL/min,mL/min,建議起始劑量為每日一次0.5 mg，患者接著可以視需求調整到最大劑量每日兩次0.5mg,血液透析病患若對本藥耐受性良好，可以使用最大劑量每日一次0.5mg,201804191509,201804191514
OCHA5,成人,Clcr,0,30.00,mL/min,mL/min,建議起始劑量為每日一次0.5 mg，患者接著可以視需求調整到最大劑量每日兩次0.5mg,血液透析病患若對本藥耐受性良好，可以使用最大劑量每日一次0.5mg,201804191515,201804191515
OCHE,成人,Clcr,0,14.99,mL/min,mL/min,不建議使用,,,
OCHE,成人,Clcr,15.00,30.00,mL/min,mL/min,one-half the usual dose,,,
OCIA5,成人,Clcr,0,30.00,mL/min,mL/min,for erectile dysfunction: as-needed use， MAX dose is5 mg ORALLY; do not repeat more frequently than once every 72 hours,for benign prostatic hyperplasia:once daily use， not recommended,201804192053,201804192057
OCIA5,成人,Clcr,30.00,50.00,mL/min,mL/min,for erectile dysfunction: 5 mg ORALLY once daily， MAX dose is 10 mg ORALLY not more frequently than once every 48 hours,for benign prostatic hyperplasia:2.5 mg ORALLY once daily; may increase to 5 mg ORALLY once daily,201804192055,201804192056
OCINO,成人,Clcr,0,30.00,mL/min,mL/min,MAX DOSE: 500mg/day,,201905220955,201905220955
OCINO,成人,Clcr,30.00,60.00,mL/min,mL/min,MAX DOSE: 1000mg/day,,201905220955,
OCIPR,成人,Scr,1.40,1.90,mg/dL,mg/dL,1000 mg/day,,,
OCIPR,成人,Scr,2.00,10.00,mg/dL,mg/dL,500mg/day,,,
OCIZO,成人,Clcr,0,50.00,mL/min,mL/min,There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Use with caution.,,202003121624,
OCOD,成人,Clcr,0,30.00,mL/min,mL/min,不建議使用,嚴重腎功能障礙病患建議使用loop diuretics效果，會較thiazide來的好,201804121609,201804121609
OCODI,成人,eGFR,0,10.00,mL/min/1.73m2,mL/min/1.73m2,50% of normal dose,,201804141528,201804141528
OCODI,成人,eGFR,10.00,50.00,mL/min/1.73m2,mL/min/1.73m2,75% of normal dose,,201804141528,201804141528
OCOLC,成人,Clcr,0,30.00,mL/min,mL/min,0.3 mg/day orally initially; increase dose with adequate monitoring,Do not repeat course more than once every 2 weeks(gout),201804142307,201804142307
OCOMP,成人,Clcr,0,0,mL/min,mL/min,腎功能不全患者應謹慎使用,,201804231418,201804231418
OCON,成人,Clcr,0,20.00,mL/min,mL/min,建議初始劑量: 2.5 mg ORALLY once daily,最高劑量:10 mg ORALLY once daily,201804121446,201804121446
OCON1,成人,Clcr,0,20.00,mL/min,mL/min,建議初始劑量: 2.5 mg ORALLY once daily,最高劑量:10 mg ORALLY once daily,201804121448,201804121448
OCONI,成人,Clcr,10.00,0,mL/min,mL/min,不建議使用於嚴重腎功能不全患者(CLCR <10 ml/min),[仿單],201912181529,
OCOP,成人,Clcr,0,29.99,mL/min,mL/min,Contraindication.,,201812250937,201812250938
OCOR5,成人,Clcr,0,15.00,mL/min,mL/min,應謹慎使用,,201804120042,201804120042
OCRA5,成人,Clcr,0,10.00,mL/min,mL/min,(包含血液透析及腹膜透析) 原給藥方式:500mg Q12H:首次劑量500mg，之後125mg Q24H;  原給藥方式:500mg Q24H:首次劑量500mg，之後125mg Q24H;  原給藥方式:250mg Q24H:首次劑量250mg，之後125mg Q48H;,仿單,202112141058,202112141051
OCRA5,成人,Clcr,10.00,19.00,mL/min,mL/min,if normal adult dose is 750 mg every 24 hours change to 750 mg initially then 500 mg every 48 hours; 500 mg every 24 hours change to 500 mg initially then 250 mg every 48 hours; 250 mg every 24 hours change to 250 mg every 48 hours (no dose adjustment necessary if treating uncomplicated UTI).,Micromedexs 20211214,202112141042,202112141050
OCRA5,成人,Clcr,10.01,19.00,mL/min,mL/min,原給藥方式:500mg Q12H:首次劑量500mg，之後125mg Q12H;  原給藥方式:500mg Q24H:首次劑量500mg，之後125mg Q24H;  原給藥方式:250mg Q24H:首次劑量250mg，之後125mg Q48H;,仿單,202112141056,202112141051
OCRA5,成人,Clcr,20.00,50.00,mL/min,mL/min,原給藥方式:500mg Q12H:首次劑量500mg，之後250mg Q12H;  原給藥方式:500mg Q24H:首次劑量500mg，之後250mg Q24H;  原給藥方式:250mg Q24H:首次劑量250mg，之後125mg Q24H;,仿單,,202112141051
OCRA5,成人,Clcr,20.00,49.00,mL/min,mL/min,if normal adult dose is 750 mg every 24 hours change to every 48 hours; 500 mg every 24 hours change to 500 mg initially then 250 mg every 24 hours; 250 mg every 24 hours is no adjustment necessary.,Micromedexs 20211214,202112141036,
OCRE,成人,Clcr,0,30.00,mL/min,mL/min,起始劑量:5 mg orally once daily,最高劑量:10 mg orally once daily,201804130712,201804130712
OCUR,成人,eGFR,30.00,0,mL/min/1.73m2,mL/min/1.73m2,本藥只能用於腎絲球過濾率大於30毫升/分鐘的病患,仿單,202007290942,202007291116
OCUR,成人,Clcr,0,0,mL/min,mL/min,Hemodialysis: Usual dose every 24 hours; additional dose both during and after each hemodialysis session,Micromedex 20200729,202007291118,202007291114
OCUR,成人,Clcr,10.00,0,mL/min,mL/min,CrCl less than 10 mL/min， usual dose every 24 hours,Micromedex 20200729,202007291117,202007291118
OCUR,成人,Clcr,30.00,10.00,mL/min,mL/min,CrCl 10 to 30 mL/min， usual dose every 12 hours,Micromedex 20200729,202007291117,202007291114
OCYM,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,不建議使用,,201804150044,201804150044
ODEF,成人,Clcr,0,0,mL/min,mL/min,嚴重腎功能障礙病患建議劑量為 300 mg every 12 hours，增加劑量時須謹慎小心,,201804131623,201804131623
ODEN,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Mild to severe impairment: 5 mg every other day.,,201804231512,
ODEPY,成人,eGFR,0,9.99,mL/min/1.73m2,mL/min/1.73m2,Administer every 8 hours.,,202003201157,
ODEPY,成人,eGFR,10.00,50.00,mL/min/1.73m2,mL/min/1.73m2,Administer every 6 hours.,,202003201157,
ODEPY,兒童,eGFR,0,9.99,mL/min/1.73m2,mL/min/1.73m2,Administer every 8 hours.,,202003201158,
ODET,成人,eGFR,30.00,0,mL/min/1.73m2,mL/min/1.73m2,腎絲球過濾率每分鐘小於或等於30 毫升病患的建議劑量是每次1 毫克、一天二次,仿單,202210171133,202210171433
ODET4,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,重度腎功能不全患者建議劑量是每次2毫克、一天一次,,201804212256,201804212256
ODIBO,成人,Scr,2.00,99.99,mg/dL,mg/dL,Serum creatinine >2 mg/dL or CrCl <25 ml/minute/1.73 m2: Use is not recommended; systemic AUC increased 6-fold in patients with CrCl <25 mL/ minute/1.73 m2.,,201810261032,201810261032
ODIC1,成人,Clcr,0,30.00,mL/min,mL/min,Significant impairment or advanced renal disease: Use is not recommended.,,201912091134,201912091134
ODIF,成人,Clcr,0,10.00,mL/min,mL/min,Give initial loading dose of 50 to 400 mg， followed by the usual dosage after each hemodialysis session and 50% of the usual dose on nondialysis days if CrCl is 50 mL/min or less.,,,
ODIF,成人,Clcr,10.00,20.00,mL/min,mL/min,給藥間隔72小時或正常每日劑量的三分之一,,,
ODIF,成人,Clcr,21.00,40.00,mL/min,mL/min,給藥間隔48小時或正常每日劑量的一半,,,
ODIG,成人,Scr,0,0,mg/dL,mg/dL,腎功能障礙及無尿排泄病人，半衰期可能延長至100小時，因此可能需要減少維持劑量。,,201804120036,202003131035
ODIG,成人,eGFR,0,10.00,mL/min/1.73m2,mL/min/1.73m2,[UpToDate] 0.0625 mg every 48 hours,(10% to 25% of the usual dose every 48 hours),202003131030,202003131031
ODIG,成人,eGFR,10.00,50.00,mL/min/1.73m2,mL/min/1.73m2,[UpToDate] 0.0625 mg every 24 to 36 hours,(25% to 75% of the usual dose every 24 to 36 hours),202003131030,202003131032
ODIG,成人,eGFR,50.00,999.00,mL/min/1.73m2,mL/min/1.73m2,[UpToDate] No dosage adjustment necessary.,,202003131031,202003131030
ODIG,成人,Clcr,0,30.00,mL/min,mL/min,[UpToDate] 0.125 mg every 48 hours,,202003131033,202003131031
ODIG,成人,Clcr,30.00,80.00,mL/min,mL/min,[UpToDate] 0.125 mg once daily,,202003131033,202003131031
ODIG,成人,Clcr,80.00,120.00,mL/min,mL/min,[UpToDate] Alternate between doses of 0.25 mg and 0.125 mg once daily,,202003131033,202003131031
ODIG,成人,Clcr,120.00,999.00,mL/min,mL/min,[UpToDate] 0.25 mg once daily,,202003131032,202003131031
ODIG2,成人,Scr,0,0,mg/dL,mg/dL,腎功能障礙及無尿排泄病人，半衰期可能延長至100小時，因此可能需要減少維持劑量。,,202003131034,202003131035
ODIG2,成人,eGFR,0,10.00,mL/min/1.73m2,mL/min/1.73m2,[UpToDate] 0.0625 mg every 48 hours,(10% to 25% of the usual dose every 48 hours),202003131033,202003131031
ODIG2,成人,eGFR,10.00,50.00,mL/min/1.73m2,mL/min/1.73m2,[UpToDate] 0.0625 mg every 24 to 36 hours,(25% to 75% of the usual dose every 24 to 36 hours),202003131034,202003131032
ODIG2,成人,eGFR,50.00,999.00,mL/min/1.73m2,mL/min/1.73m2,[UpToDate] No dosage adjustment necessary.,,202003131034,202003131030
ODIG2,成人,Clcr,0,30.00,mL/min,mL/min,[UpToDate] 0.125 mg every 48 hours,,202003131034,202003131031
ODIG2,成人,Clcr,30.00,80.00,mL/min,mL/min,[UpToDate] 0.125 mg once daily,,202003131034,202003131031
ODIG2,成人,Clcr,80.00,120.00,mL/min,mL/min,[UpToDate] Alternate between doses of 0.25 mg and 0.125 mg once daily,,202003131034,202003131031
ODIG2,成人,Clcr,120.00,999.00,mL/min,mL/min,[UpToDate] 0.25 mg once daily,,202003131034,202003131031
ODIP,成人,Clcr,0,0,mL/min,mL/min,重度腎功能不全之病患不建議使用(特別是無尿症),,201804160549,201804160549
ODOG5,成人,Clcr,0,10.00,mL/min,mL/min,34% of normal dose,,201804142351,201804142351
ODOG5,成人,Clcr,10.00,30.00,mL/min,mL/min,50% of normal dose,,201804142351,
ODOG5,成人,Clcr,30.00,60.00,mL/min,mL/min,70% of normal dose,,201804142350,
ODOLC,成人,Clcr,30.00,120.00,mL/min,mL/min,無須調整劑量,,,
ODOM,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Depending on severity of impairment， frequency should be reduced to 1 to 2 times daily and dosage reduction considered with repeated administration.,,201812281051,
ODOP,成人,Clcr,0,15.00,mL/min,mL/min,200 mg orally every 7 days,,202003151140,201806141747
ODOP,成人,Clcr,15.00,29.00,mL/min,mL/min,200 mg orally on first day then 100 mg every other day,,202003151140,201806141747
ODOP,成人,Clcr,30.00,50.00,mL/min,mL/min,200 mg orally on first day then 100 mg/day,,202003151140,201806141747
ODOR4,成人,Clcr,0,0,mL/min,mL/min,因主要副作用為引起浮腫.血壓上傷，腎臟疾病患者應注意,,201804231421,201804231421
ODUO,成人,Clcr,0,10.00,mL/min,mL/min,未期腎病患者未進行研究,,201804212309,201804212309
ODUO,成人,Clcr,10.00,30.00,mL/min,mL/min,中度到重度腎功能受損患者無須調整劑量,,201804212309,
OEBI,成人,Clcr,5.00,29.00,mL/min,mL/min,reduce dosage to 5 mg ORALLY twice daily,Micromedex 20220209,201804160555,202202091116
OEBI,成人,Clcr,5.00,49.00,mL/min,mL/min,中度受損(Clcr:30-49)及重度受損(Clcr:5-29)患者每日劑量應為10mg,仿單,202202091133,202202091116
OEFE7,成人,eGFR,10.00,70.00,mL/min/1.73m2,mL/min/1.73m2,建議降低25-50%用量開始治療。,血液透析法治療之患者，建議以降低50%之用量開始治療，且等血液透析(四小時)完成後再服用藥物,201804150053,
OEFI3,成人,Clcr,0,50.00,mL/min,mL/min,No dosage adjustment is necessary for patients with renal impairment; however， there is limited information in patients with end-stage renal disease,,202004021107,
OELI,成人,Scr,1.50,7.00,mg/dL,mg/dL,血清肌酸酐大於或等於1.5mg/dL，且併有年齡大於等於80歲或體重小於等於60公斤，建議劑量為2.5mg，一天兩次。,仿單,202201251635,202201251637
OELI,成人,Clcr,0,14.99,mL/min,mL/min,Avoid use in severe renal impairment.,,201807011130,
OELI,成人,Clcr,15.00,29.99,mL/min,mL/min,2.5 mg twice daily.,,201807011129,
OELI2,成人,Scr,1.50,7.00,mg/dL,mg/dL,血清肌酸酐大於或等於1.5mg/dL，且併有年齡大於等於80歲或體重小於等於60公斤，建議劑量為2.5mg，一天兩次。,仿單,202201251640,202201251637
OELI2,成人,Clcr,0,14.99,mL/min,mL/min,Avoid use in severe renal impairment.,,201908071537,
OELI2,成人,Clcr,15.00,29.99,mL/min,mL/min,2.5 mg twice daily.,,201908071537,
OEND,成人,Clcr,0,10.00,mL/min,mL/min,嚴重腎功能不全者，則降低50%的劑量,,201804261547,202106181414
OENTR,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,建議起始劑量為每日2次50mg,依患者耐受情況，每2至4周加倍Entresto的劑量，達到每日2次200mg的目標維持劑量,201804130633,201804130633
OENZI,成人,Clcr,0,15.00,mL/min,mL/min,200 mg orally every 7 days,,201806141747,201806141747
OENZI,成人,Clcr,15.00,29.00,mL/min,mL/min,200 mg orally on first day then 100 mg every other day,,201806141748,201806141747
OENZI,成人,Clcr,30.00,50.00,mL/min,mL/min,200 mg orally on first day then 100 mg/day,,201806141748,201806141747
OEPB,成人,Clcr,0,30.00,mL/min,mL/min,20 to 25 mg/kg orally 3 times per week.,25mg/kg orally 3 times per week,,
OEPC,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,目前尚未針對重度腎功能不全或患有須接受血液透析治療之末期腎病（ESRD）的患者評估過Epclusa的安全性與療效,,201910061123,
OEPR,成人,Clcr,0,30.00,mL/min,mL/min,Severe impairment: CrCl <30 mL/minute: Use with caution.,,201910061207,
OERAF,成人,Clcr,0,10.00,mL/min,mL/min,Treatment/Prophylaxis: ESRD not undergoing dialysis: Use is not recommended (has not been studied),,201811211422,201811231050
OERAF,成人,Clcr,10.01,30.00,mL/min,mL/min,Treatment: 30 mg once daily Prophylaxis: 30 mg every other day,,201811211422,201811231050
OERAF,成人,Clcr,30.01,60.00,mL/min,mL/min,Treatment: 30 mg twice daily Prophylaxis: 30 mg once daily,,201811211421,201811231050
OESM,成人,Clcr,0,0,mL/min,mL/min,由於缺乏特定研究，因此ulipristal acetate並不建議使用於嚴重腎功能不全的病患，除非病患接受密切監測,,201804242338,201804242338
OEVO,成人,Clcr,0,0,mL/min,mL/min,腎功能不全者持續維持藥物血中高濃度，而可能提高副作用的發生率,,201804191426,201804191426
OFAM,成人,Clcr,0,9.99,mL/min,mL/min,血液透析病人:"每次洗腎之後應立即投予 famciclovir；帶狀\疹患者:建議劑量為 250 毫克;生殖器\疹患者:125毫克",,,
OFAM,成人,Clcr,10.00,30.00,mL/min,mL/min,"治療帶狀\疹與初發性之生殖器\疹感染症：每天125毫克，一天三次;治療急性復發之生殖器\疹感染症時，無須調整劑量",,,
OFAMO,成人,Clcr,0,0,mL/min,mL/min,洗腎患者: 1 次 20mg 洗腎後 1 次,仿單,201909251622,202008031024
OFAMO,成人,Clcr,29.99,0,mL/min,mL/min,If usual dose is 10 mg twice daily or 20 mg once daily: 10 mg every other day; If usual dose is 20 mg twice daily: 10 mg once daily or 20 mg every other day,UpToDate 20200803,202008031028,202008031024
OFAMO,成人,Clcr,30.00,0,mL/min,mL/min,1 次 20mg， 2∼3 日 1 次,仿單,201909251621,202008031024
OFAMO,成人,Clcr,59.99,30.00,mL/min,mL/min,If usual dose is 10 mg twice daily or 20 mg once daily: 10 mg once daily or 20 mg every other day; If usual dose is 20 mg twice daily: 20 mg once daily or 40 mg every other day,UpToDate 20200803,202008031029,202008031024
OFAMO,成人,Clcr,60.00,30.00,mL/min,mL/min,1 次 20mg ，1 日 1 次,仿單,201909251621,202008031024
OFAX,成人,Clcr,0,0,mL/min,mL/min,輕度或中度腎功能不全病患 建議降低 usual dosage by 25% to 50%,血液透析病患 建議Decrease usual dosage by 50%,201804150048,201804150050
OFEB,成人,Clcr,15.00,29.00,mL/min,mL/min,Limit dose to 40 mg once daily,,201804142310,201804142310
OFLU,成人,Scr,2.50,0,mg/dL,mg/dL,應避免使用,,201804120103,201804120104
OFLUC,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer's,,201804191057,
OFOL,成人,Clcr,0,0,mL/min,mL/min,病人若有腹水，胸膜滲透液，腎功能障礙或Hydration不夠時會延遲methotrexate排出，應考慮增加Folina劑量或延長治療時間,若建議劑量高於口服使用許可劑量，應改以靜脈注射給藥,201804191520,201804191520
OFOR,成人,eGFR,0,25.00,mL/min/1.73m2,mL/min/1.73m2,針對此類病人不建議開始治療，然而Forxiga治療後，eGFR降低至小於25 mL/min/1.73 m2的病人，可持續使用以降低eGFR下降、ESKD、心血管死亡和心衰竭住院的風險。,仿單,202109140952,202111301201
OFOR,成人,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,透析病患禁止使用Forxiga.,仿單,202109140957,202111301203
OFOR,成人,eGFR,0,0.01,mL/min/1.73m2,mL/min/1.73m2,Renal impairment (ESRD or dialysis) in any population: Use is contraindicated.,Micromedex 20210914,202109141105,202109141106
OFOR,成人,eGFR,0,45.00,mL/min/1.73m2,mL/min/1.73m2,used for glycemic control: Use not recommended. type 2 diabetes when used to reduce risk of hospitalization for heart failure: Insufficient data to support dose adjustment recommendation.,Micromedex 20210914,202109141055,202109141100
OFOR,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,used for glycemic control: Use is contraindicated. heart failure with reduced ejection fraction (with or without type 2 diabetes) when used to reduce risk of cardiovascular death/hospitalization: Insufficient data to support dose adjustment recommendation.,Micromedex 20210914,202109141057,202109141059
OFOR,成人,eGFR,25.00,45.00,mL/min/1.73m2,mL/min/1.73m2,每天口服1次10毫克。不建議使用Forxiga作為eGFR低於45 mL/min/1.73 m2的第二型糖尿病病人的血糖控制，Forxiga基於其作用機制，在此情況下可能無效。,仿單,201804112343,202111301201
OFOR,成人,eGFR,45.00,99.00,mL/min/1.73m2,mL/min/1.73m2,為改善血糖控制，Forxiga的建議起始劑量是5毫克每天口服1次。在耐受Forxiga 5毫克每天1次的病人，需要對於額外血糖控制時，劑量可增至10毫克每天口服1次。對於所有其他適應症的建議起始劑量是每天口服1次10毫克。,仿單,202111301159,202109141054
OFOSP,成人,Clcr,0,35.00,mL/min,mL/min,不建議使用,,201804120003,201804120008
OFUCO,成人,eGFR,0,9.99,mL/min/1.73m2,mL/min/1.73m2,Administer every 8 hours.,,201804021212,
OFUCO,成人,eGFR,10.00,50.00,mL/min/1.73m2,mL/min/1.73m2,Administer every 6 hours.,,201804021212,
OFUCO,兒童,eGFR,0,9.99,mL/min/1.73m2,mL/min/1.73m2,Administer every 8 hours.,,201804021213,
OFUN,成人,Clcr,50.00,0,mL/min,mL/min,穩定且慢性腎功能異常的病人，應使用建議劑量的一半。並應在用藥前後追蹤檢查其肝功能。,[仿單],202110201120,202110201129
OFYC,成人,Clcr,0,0,mL/min,mL/min,中度腎功能不全病患建議:Close monitoring and slower dose titration may be necessary based on patient's response and tolerability,重度腎功能不全病患不建議使用,201804160428,201804160428
OGALM,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,不建議使用,,201804112345,201804112345
OGLIV,成人,Clcr,0,19.99,mL/min,mL/min,Use caution; a dose of 100 mg daily has been tolerated in a limited number of patients with severe impairment,,201804301513,201804301513
OGLIV,成人,Clcr,20.00,39.99,mL/min,mL/min,Decrease recommended starting dose by 50%; dose may be increased as tolerated; maximum recommended dose: 400 mg.,,201804301513,
OGLIV,成人,Clcr,40.00,59.99,mL/min,mL/min,Maximum recommended dose: 600 mg.,,201804301512,201804301513
OGLUB1,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,不建議使用,,201804112338,201804112338
OGLUC,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,Use is contraindicated,Micromedex 20201006,202010021202,202010061216
OGLUC,成人,eGFR,30.00,45.00,mL/min/1.73m2,mL/min/1.73m2,Use not recommended,Micromedex 20201006,202010061217,202010061216
OGLUC,成人,eGFR,30.01,45.00,mL/min/1.73m2,mL/min/1.73m2,應減量使用,仿單,202010061236,202010061216
OGLUC,成人,eGFR,45.00,45.00,mL/min/1.73m2,mL/min/1.73m2,eGFR falls below 45 mL/min/1.73 m(2) after initiation: Assess benefits and risks of continuing treatment,Micromedex 20201006,202010061217,202010061219
OGLUF,成人,Clcr,0,0,mL/min,mL/min,腎衰竭患者服藥後要務之半衰期延長，可能導致低血糖的副作用，須謹慎使用。,,201804112331,201804112331
OGLUM,成人,Scr,1.40,0,mg/dL,mg/dL,不建議使用,女性,201804112348,201804112348
OGLUM,成人,Scr,1.50,0,mg/dL,mg/dL,不建議使用,男性,201804112347,201804112347
OGOU,成人,Clcr,0,0,mL/min,mL/min,腎功能不全者需應斟酌減低劑量，嚴重腎功能不全者不建議使用,,201804142313,
OGXB,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,低於30 mL/min/1.73 m2不應使用,[仿單],202007051226,202109011108
OGXB,成人,eGFR,0,29.99,mL/min/1.73m2,mL/min/1.73m2,Renal impairment， eGFR less than 30 mL/min/1.73 m(2)， including ESRD: Use not recommended,[Micromedex 20210901],202007061544,202109011110
OHAR4,成人,Clcr,0,0,mL/min,mL/min,對腎功能低下者宜由0.1mg 開始投與，經過充分的觀察才增量至0.2 mg。由於本藥的單位含量較高，因此不建議使用於上述病患,,201804212318,201804212318
OHARV,成人,eGFR,0,29.99,mL/min/1.73m2,mL/min/1.73m2,無法提供任何劑量建議,,,
OHYD,成人,Clcr,0,10.00,mL/min,mL/min,Reduce initial dose by 50% (administer after dialysis on dialysis days); titrate to response/avoidance of toxicity,,201804301511,
OHYD,成人,Clcr,0,60.00,mL/min,mL/min,Reduce initial dose by 50%; titrate to response/avoidance of toxicity,,201804301510,
OHYXQ,成人,Clcr,50.00,0,mL/min,mL/min,There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.,,202004071046,
OIMU,成人,Clcr,0,0,mL/min,mL/min,Hemodialysis (partially dialyzable; ~45% removed in 8 hours): Administer 50% of normal dose; supplement: 0.25 mg/kg.,,201804231640,
OIMU,成人,Clcr,0,9.99,mL/min,mL/min,Administer 50% of normal dose.,,201804231640,
OIMU,成人,Clcr,10.00,50.00,mL/min,mL/min,Administer 75% of normal dose.,,201804231639,
OINDO2,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,Avoid use.,KDIGO 2012 guidelines provide the following recommendations for NSAIDs,201910031032,
OINDO2,成人,eGFR,30.00,60.00,mL/min/1.73m2,mL/min/1.73m2,Temporarily discontinue in patients with intercurrent disease that increases risk of acute kidney injury.,KDIGO 2012 guidelines provide the following recommendations for NSAIDs,201910031032,
OINV,成人,Clcr,0,10.00,mL/min,mL/min,不建議使用,,201804142355,201804142355
OINV,成人,Clcr,10.00,50.00,mL/min,mL/min,起始劑量:1.5 mg once daily,最高劑量:3 mg once daily,201804142355,
OINV,成人,Clcr,50.00,80.00,mL/min,mL/min,起始劑量:3 mg once daily,最高劑量:6 mg once daily,201804142354,
OISO2,成人,Clcr,0,0,mL/min,mL/min,腎功能不全病人應謹慎使用(約70%的投與藥物代謝產物由尿液排除),,201804121520,201804121520
OJAN,成人,eGFR,0,29.99,mL/min/1.73m2,mL/min/1.73m2,每日一次25mg,仿單建議,201805301116,
OJAN,成人,eGFR,30.00,44.99,mL/min/1.73m2,mL/min/1.73m2,每日一次50mg,仿單建議,201805301115,201805301125
OJAR,成人,eGFR,0,45.00,mL/min/1.73m2,mL/min/1.73m2,不建議使用,,201804112344,201804112344
OJAR2,成人,eGFR,0,29.99,mL/min/1.73m2,mL/min/1.73m2,Renal impairment (severe)， ESRD， or receiving dialysis: Use contraindicated.,Micromedex 20200710,201806251352,202007101024
OJAR2,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,腎絲球過濾率估計值低於30mL/min/1.73m2或洗腎的病人不建議使用.,仿單,202007101025,202212011530
OJAR2,成人,eGFR,30.00,45.00,mL/min/1.73m2,mL/min/1.73m2,Do not initiate therapy; discontinue use if eGFR drops and remains below 45 mL/min/1.73m(2),Micromedex 20200710,201806251351,202007101023
OJAR2,成人,eGFR,30.00,99.00,mL/min/1.73m2,mL/min/1.73m2,腎絲球過濾率估計值大於等於30mL/min/1.73m2的病人無需調整劑量.,仿單,202007101026,202007101025
OKCB,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Moderate-severe impairment: Avoid use.,,201803191053,201803191053
OKCIT,成人,Clcr,0,0,mL/min,mL/min,腎功能不全者可能會引起高血鉀或鹼中毒症狀，應定期測定血中電解質含量，以避免副作用發生,,201804212343,201804212343
OKEP,成人,Clcr,0,30.00,mL/min,mL/min,250 to 500 mg orally every 12 hours,,201804160414,201804160416
OKEP,成人,Clcr,30.00,50.00,mL/min,mL/min,250 to 750 mg orally every 12 hours,,201804160414,
OKEP,成人,Clcr,50.00,80.00,mL/min,mL/min,500 to 1000 mg orally every 12 hours,,201804160413,
OKET,成人,Clcr,0,30.00,mL/min,mL/min,Advanced impairment or patients at risk for renal failure due to volume depletion: Use is contraindicated.,,201912091114,201912091115
OKIS,成人,eGFR,15.00,29.99,mL/min/1.73m2,mL/min/1.73m2,eGFR 15 to <30 mL/minute/1.73 m2: Reduce initial dose to 200 mg once daily.,,201912230934,
OKIS0,成人,eGFR,15.00,29.99,mL/min/1.73m2,mL/min/1.73m2,eGFR 15 to <30 mL/minute/1.73 m2: Reduce initial dose to 200 mg once daily.,,202107281639,
OKLA5,成人,Clcr,0,30.00,mL/min,mL/min,dose should be reduced 50%,,,
OKLA5X,成人,Clcr,0,30.00,mL/min,mL/min,肌酸酐廓清率低於 30 mL/min之嚴重腎功能不全病人，劑量需減半，一般建議劑量為 250 mg每天一次，因KlaricidXL不可剝半，故不可用於嚴重腎功能不全病人，須改用Klaricid的速放劑型。 在較嚴重的感染建議劑量為250mg每天兩次，這些病人不得連續使用超過14天。,仿單,202211301030,202211301030
OKLA5X,成人,Clcr,0,29.99,mL/min,mL/min,severe renal impairment: CrCl less than 30 mL/min， dose should be reduced 50%,Micromedex 2022/11/30,202211301021,202211301023
OKLAR,成人,Clcr,0,30.00,mL/min,mL/min,In combination with atazanavir or ritonavir:Decrease clarithromycin dose by 75%.,,201807111149,201807111150
OKLAR,成人,Clcr,0,9.99,mL/min,mL/min,Hemodialysis: Administer after HD session is completed.,,201807111147,201807111147
OKLAR,成人,Clcr,0,29.99,mL/min,mL/min,Decrease clarithromycin dose by 50%.,,201807111142,
OKLAR,成人,Clcr,30.00,60.00,mL/min,mL/min,In combination with atazanavir or ritonavir: Decrease clarithromycin dose by 50%.,,201807111148,201807111147
OLACS,成人,Clcr,0,30.00,mL/min,mL/min,Avoid use. (KDIGO 2012 guideline),,201912091130,
OLACS,成人,Clcr,30.00,60.00,mL/min,mL/min,Temporarily discontinue in patients with intercurrent disease that increases risk of acute kidney injury. (KDIGO 2012 guideline),,201912091130,
OLAMC,成人,Clcr,0,0,mL/min,mL/min,嚴重腎功能不全病患降低維持劑量仍是有效的,,201804160440,201804160440
OLAMS,成人,Clcr,0,49.99,mL/min,mL/min,腎功能損害患者的研究尚未充份，因此不建議使用於這類患者,,,
OLAT,成人,Clcr,0,49.90,mL/min,mL/min,CrCl <50 mL/minute: Initial: 20 mg daily; maximum: 80 mg/day,,201803291528,
OLEE,成人,Clcr,0,30.00,mL/min,mL/min,Severe impairment: CrCl <30 mL/minute: Use with caution.,,201809161629,
OLEEV,成人,Clcr,0,19.99,mL/min,mL/min,Use caution; a dose of 100 mg daily has been tolerated in a limited number of patients with severe impairment,,201907181504,201804301513
OLEEV,成人,Clcr,20.00,39.99,mL/min,mL/min,Decrease recommended starting dose by 50%; dose may be increased as tolerated; maximum recommended dose: 400 mg.,,201907181504,
OLEEV,成人,Clcr,40.00,59.99,mL/min,mL/min,Maximum recommended dose: 600 mg.,,201907181504,201804301513
OLEUK,成人,Clcr,0,0,mL/min,mL/min,有腎功能損傷跡象的病患須小心地監測，因易於罹患與氮血症有關之附加性骨髓抑制,,201804261552,
OLEX3,成人,Clcr,0,0,mL/min,mL/min,腎功能不全患者建議從最低劑量開始使用,,201804150021,201804150021
OLEXA,成人,Clcr,0,0,mL/min,mL/min,嚴重腎功能不全患者應謹慎使用,,201804150033,201804150033
OLINI,成人,Clcr,0,30.00,mL/min,mL/min,劑量調高至每天20mg者應小心謹慎，使用時應加注意,,201804130719,201804130719
OLIPS,成人,Clcr,0,15.00,mL/min,mL/min,重度腎功能不全病患，不建議使用,,201804130730,201804130730
OLIPS,成人,Clcr,15.00,0,mL/min,mL/min,輕度和中度腎功能不全病患，建議每日一次每次使用0.5顆Lipanthyl 160mg,,201804130727,201804130730
OLIVA,成人,Clcr,15.00,29.00,mL/min,mL/min,起始劑量:1 mg orally once daily (包含透析病人),最高劑量:2 mg/day,201804130734,201804130734
OLIVA,成人,Clcr,30.00,59.00,mL/min,mL/min,起始劑量:1 mg orally once daily,最高劑量:2 mg/day,201804130733,
OLIX,成人,Clcr,0,14.90,mL/min,mL/min,Use is not recommended,,201804191153,
OLIX,成人,Clcr,15.00,50.00,mL/min,mL/min,30 mg once daily.,,201804191153,
OLON,兒童,Clcr,60.00,0,mL/min,mL/min,No dosage adjustment of etodolac is necessary in patients with mild-to-moderate renal failure. However， etodolac should be used with caution because it may cause cumulative effects on renal function especially in patients with pre-existing mild-to-moderate renal dysfunction,Micromedex 2020/11/27,202011271213,202011271213
OLONS,成人,Clcr,30.00,0,mL/min,mL/min,There are no dosage adjustments provided in the manufacturer's labeling,,201908051522,
OLOX,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustment provided in manufacturer's labeling.,,201804191056,
OLYR,成人,Clcr,0,14.99,mL/min,mL/min,Adults: 25 to 75 mg once daily,Micromedex 20200803,202008031440,202008031441
OLYR,成人,Clcr,0,15.00,mL/min,mL/min,原使用600mg BID or TID: 75mg QD. 原使用450mg BID or TID: 50-75mg QD. 原使用300mg BID or TID: 25-50mg QD. 原使用150mg BID or TID: 25mg QD.,仿單,202008031433,202008031432
OLYR,成人,Clcr,14.99,30.00,mL/min,mL/min,Adults: 25 to 150 mg/day given once daily or in 2 divided doses,Micromedex 20200803,202008031439,202008031440
OLYR,成人,Clcr,15.00,30.00,mL/min,mL/min,原使用600mg BID or TID: 150mg QD or BID. 原使用450mg BID or TID: 100-150mg QD or BID. 原使用300mg BID or TID: 75mg QD or BID. 原使用150mg BID or TID: 25-50mg QD or BID.,仿單,201804160453,202008031432
OLYR,成人,Clcr,29.99,60.00,mL/min,mL/min,Adults: 75 to 300 mg/day in 2 to 3 divided doses,Micromedex 20200803,202008031438,202008031438
OLYR,成人,Clcr,30.00,60.00,mL/min,mL/min,原使用600mg BID or TID: 300mg BID or TID. 原使用450mg BID or TID: 225mg BID or TID. 原使用300mg BID or TID: 150mg BID or TID. 原使用150mg BID or TID: 75mg BID or TID.,仿單,201804160452,202008031431
OLYR,成人,Clcr,60.00,99.99,mL/min,mL/min,Adults: No adjustment required,Micromedex 20200803,202008031437,202008031437
OMEDA,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustment provided in manufacturer's labeling.,,201804191053,
OMELE,成人,Clcr,0,10.00,mL/min,mL/min,應依病患個別狀況調整劑量,,201804120050,201804120050
OMEPR,成人,Clcr,0,0,mL/min,mL/min,腎功能不全患者應謹慎使用,,201804231424,201804231424
OMETH,成人,Clcr,0,10.00,mL/min,mL/min,Increase dosage interval to 12 to 24 hours,,201804130700,201804130700
OMETH,成人,Clcr,10.00,50.00,mL/min,mL/min,Increase dosage interval to 8 to 12 hours,,201804130700,201804130659
OMETH,成人,Clcr,50.00,0,mL/min,mL/min,Increase dosage interval to 8 hours,,201804130659,201804130659
OMEV4,成人,Clcr,0,15.00,mL/min,mL/min,起始劑量:10 mg orally once daily,,201804130736,201804130736
OMEZA,成人,eGFR,30.00,0,mL/min/1.73m2,mL/min/1.73m2,禁忌使用,未有特別針對肝或腎功能不全所做的試驗,201904021508,201904021509
OMIDO,成人,Clcr,0,0,mL/min,mL/min,嚴重腎功能不全患者需注意投與劑量，謹慎使用，建議起始劑量 2.5 mg,,201804130647,201804130701
OMIN6,成人,Clcr,0,50.00,mL/min,mL/min,中度到嚴重的腎功能不全病患不建議使用,,201804242350,201804242350
OMIRA,成人,Clcr,0,30.00,mL/min,mL/min,不建議使用,,201804160531,201804160531
OMIRA,成人,Clcr,30.00,50.00,mL/min,mL/min,開始時必須每隔一天服用一次MIRAPEX PR。須謹慎用藥，並仔細評估治療反應及耐受性，才可於一週後調高每日劑量，並進一步以每次0.375 mg的增幅將劑量調至最高一天2.25 mg。,劑量調整頻率不可多於一週一次。,201804160530,
OMIRT,成人,Clcr,0,10.00,mL/min,mL/min,口服單劑15毫克mirtazapine後，相較於正常受試者，腎臟重度受損(肌酸酐清除率 <10 ml/min)，mirtazapine的清除率約降低50%。Mirtazapine的平均血中濃度增加115%。這類患者給予mirtazapine 時須留意。,仿單,201806261029,201806261030
OMIRT,成人,Clcr,10.00,40.00,mL/min,mL/min,口服單劑15毫克mirtazapine後，相較於正常受試者，腎臟中度受損(肌酸酐清除率 >10 ml/min，<40 ml/min)，mirtazapine的清除率約降低30%。Mirtazapine的平均血中濃度增加55%。這類患者給予mirtazapine 時須留意。,仿單,201806261026,201806261030
OMOBI,成人,Clcr,0,15.00,mL/min,mL/min,不建議使用,,201804141621,201804141621
OMON,成人,Clcr,0,10.00,mL/min,mL/min,(含血液透析患者)不建議使用,,,
OMOR1,成人,eGFR,0,10.00,mL/min/1.73m2,mL/min/1.73m2,Reduce dose by 50% or consider alternative opioid analgesics,,201804141510,201804141510
OMOR1,成人,eGFR,10.00,50.00,mL/min/1.73m2,mL/min/1.73m2,Reduce dose by 25%,,201804141509,
OMORC,成人,Clcr,0,15.00,mL/min,mL/min,CrCl below 15 mL/min: Use not recommended.,Micromedex 20210514,202105140917,202105140924
OMORC,成人,Clcr,15.00,30.00,mL/min,mL/min,CrCl 15 to 30 mL/min: Use standard dosing regimen， but decrease the amount of each dose by 50%,Micromedex 20210514,202105140916,202105140924
OMORC,成人,Clcr,30.00,999.00,mL/min,mL/min,CrCl greater than 30 mL/min: No adjustment necessary; use standard dosing regimen.,Micromedex 20210514,202105140916,202105140924
OMTX,成人,Clcr,0,0,mL/min,mL/min,腎功能受損患者應謹慎使用，並且應減低劑量,嚴重腎功能受損患者不建議使用,201804261554,201804261556
ONAT,成人,Clcr,0,30.00,mL/min,mL/min,不建議使用,,201804120107,
ONEO,成人,Clcr,0,9.00,mL/min,mL/min,increase interval to every 18-24 hours,,,
ONEO,成人,Clcr,10.00,49.00,mL/min,mL/min,increase interval to every 12-18 hours,,,
ONEO,成人,Clcr,50.00,120.00,mL/min,mL/min,increase interval to every 6 hours,,,
ONEOT,成人,Clcr,0,0,mL/min,mL/min,嚴重腎功能不全患者不建議使用,,201804191608,201804191608
ONES,成人,Clcr,0,14.99,mL/min,mL/min,ESRD (CrCl <15 mL/minute or requiring hemodialysis): 6.25 mg once daily; administered without regard to timing of hemodialysis. Use of alogliptin has not been studied in patients undergoing peritoneal dialysis.,,201809101542,201809131656
ONES,成人,Clcr,15.00,29.99,mL/min,mL/min,6.25 mg once daily,,201809101541,
ONES,成人,Clcr,30.00,59.99,mL/min,mL/min,12.5 mg once daily.,,201809101541,
ONEU,成人,Clcr,15.00,29.00,mL/min,mL/min,200 to 700 mg/day given once daily,,201804160456,201804160458
ONEU,成人,Clcr,30.00,59.00,mL/min,mL/min,400 to 1400 mg/day given in 2 divided doses,,201804160456,201804160458
ONEU,成人,Clcr,60.00,0,mL/min,mL/min,900 to 3600 mg/day given in 3 divided doses,,201804160455,201804160457
ONUX,成人,Clcr,0,20.00,mL/min,mL/min,禁用,,201804160605,201804160606
ONUX,成人,Clcr,20.00,30.00,mL/min,mL/min,正常劑量的1/6，每日一次服用,,201804160606,201804160606
ONUX,成人,Clcr,30.00,49.00,mL/min,mL/min,正常劑量的1/3，每日分兩次服用,,201804160605,
ONUX,成人,Clcr,50.00,79.00,mL/min,mL/min,正常劑量的2/3，每日分兩到三次服用,,201804160604,
OOKP,成人,Clcr,0,0,mL/min,mL/min,腎功能不全病患應考慮給予較低的起始劑量(5毫克),,201804142359,201804142359
OPAN,成人,eGFR,0,10.00,mL/min/1.73m2,mL/min/1.73m2,increase dosing interval to every 8 hours,,201804142325,201804142325
OPAN,成人,eGFR,10.00,50.00,mL/min,mL/min,increase dosing interval to every 6 hours,,201804142324,201804142324
OPAN,成人,eGFR,50.00,0,mL/min,mL/min,increase dosing interval to every 4 hours,,201804142323,201804142324
OPAN,兒童,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,give usual weight or age-based dose,,201804142326,201804142326
OPAX,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,不建議重度腎功能不全（基於 CKD-EPI 公式，eGFR < 30 mL/min）病人使用本品。,仿單,202205031047,202301041107
OPAX,成人,eGFR,30.00,60.00,mL/min/1.73m2,mL/min/1.73m2,中度腎功能不全(eGFR:30-60 mL/min)病人，劑量降低至150mg Nirmatrelvir + 100mg ritonavir，每日兩次，持續5天。處方應詳細說明Paxlovid內每種活性成分的劑量。醫師/藥師應就腎功能不全病人的給藥說明提供建議。,仿單,202205031046,202205031051
OPAXS,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,不建議重度腎功能不全（基於 CKD-EPI 公式，eGFR < 30 mL/min）病人使用本品。,仿單,202301041106,202301041107
OPAXS,成人,eGFR,30.00,60.00,mL/min/1.73m2,mL/min/1.73m2,中度腎功能不全(eGFR:30-60 mL/min)病人，劑量降低至150mg Nirmatrelvir + 100mg ritonavir，每日兩次，持續5天。處方應詳細說明Paxlovid內每種活性成分的劑量。醫師/藥師應就腎功能不全病人的給藥說明提供建議。,仿單,202301041107,202301041107
OPKM,成人,Clcr,0,15.00,mL/min,mL/min,200 mg orally every 7 days,,201804160539,201804160539
OPKM,成人,Clcr,15.00,29.00,mL/min,mL/min,200 mg orally on first day then 100 mg every other day,,201804160538,
OPKM,成人,Clcr,30.00,50.00,mL/min,mL/min,200 mg orally on first day then 100 mg/day,,201804160538,
OPON,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,Avoid use.(KDIGO 2012 guidelines),,201804141552,201912091234
OPON,成人,eGFR,30.00,60.00,mL/min/1.73m2,mL/min/1.73m2,Temporarily discontinue in patients with intercurrent disease that increases risk of acute kidney injury.(KDIGO 2012 guidelines),,201912091232,201912091234
OPR150,成人,Clcr,0,29.90,mL/min,mL/min,Nonvalvular atrial fibrillation:There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).,,201804191158,
OPR150,成人,Clcr,15.00,30.00,mL/min,mL/min,Nonvalvular atrial fibrillation:75 mg twice daily,,201804191156,
OPRAD,成人,Clcr,0,15.00,mL/min,mL/min,Nonvalvular atrial fibrillation:There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).,,201804191200,201910241136
OPRAD,成人,Clcr,15.00,30.00,mL/min,mL/min,Nonvalvular atrial fibrillation:75 mg twice daily,,201804191200,
OPRI,成人,Clcr,0,0,mL/min,mL/min,輕度至中度腎功能不全的病人應謹慎使用,重度腎功能不全病人不建議使用Priligy,201804212347,201804212347
OPRIP,成人,Clcr,0,40.00,mL/min,mL/min,Initiate at 50% of usual dosage  最大劑量為單一劑量每公斤體重0.2毫克(0.2mg/kg/dose),每日總劑量不可超過每公斤體重0.5毫克,201804141434,201804141434
OPRM,成人,Clcr,0,0,mL/min,mL/min,ESRD (including hemodialysis or continuous ambulatory peritoneal dialysis)  Diabetic Gastroparesis: 5 mg orally twice daily; Maximum 10 mg/day. Gastroesophageal reflux disease: 5 mg orally 30 minutes before each meal and at bedtime OR 10 mg twice daily; Maximum 20 mg/day.,Micromedex 20221206,202212061033,202212061036
OPRM,成人,Clcr,60.00,0,mL/min,mL/min,Diabetic Gastroparesis: 5 mg orally 30 minutes before each meal and at bedtime; Maximum: 20 mg/day. Gastroesophageal reflux disease: 5 mg orally 30 minutes before each meal and at bedtime OR 10 mg three times daily; Maximum: 30 mg/day.,Micromedex 20221206,202212061029,
OPYRZ,成人,Clcr,0,29.99,mL/min,mL/min,25 to 35 mg/kg/dose 3 times per week administered after dialysis.,,202003151009,
OPZA5,成人,Clcr,0,30.00,mL/min,mL/min,25 to 35 mg/kg orally 3 times a week,3gm/day,,
OPZAT,成人,Clcr,0,29.99,mL/min,mL/min,25 to 35 mg/kg/dose 3 times per week administered after dialysis.,,201812031139,
OQTE,成人,eGFR,0,45.00,mL/min/1.73m2,mL/min/1.73m2,禁用於eGFR低於45mL/min/1.73m2的病人,仿單,202112201105,
OQTE,成人,eGFR,0.01,45.00,mL/min/1.73m2,mL/min/1.73m2,Renal impairment， moderate to severe (estimated GFR less than 45 mL/min/1.73 m(2)): Use is contraindicated,Micromedex 20211220,202112201106,
OQUEP,成人,Clcr,0,0,mL/min,mL/min,Quetiapine XR 用於腎功能不全病人的臨床經驗有限,仿單,202007011201,
ORAD,成人,Clcr,0,0,mL/min,mL/min,腎功能障礙，腎功能低下及addison氏症應謹慎服用,,201804261513,201804261513
ORANC,成人,Clcr,0,30.00,mL/min,mL/min,部份重度腎功能不全病人服用Ranolazine 後，發生急性腎衰竭。若發生急性腎衰竭(如，血漿肌酸酐升高且伴隨血液尿素氮升高)，請停止服用Ranolazine 並接受適當治療。,仿單,202101041850,202101050822
ORANC,成人,Clcr,30.01,60.00,mL/min,mL/min,中重度腎功能不全病人，在開始使用Ranolazine時及服用Ranolazine期間，需定期監測血漿肌酸酐及血液尿素氮是否升高。,仿單,202101041851,202101050822
OREOS,成人,Clcr,29.99,0,mL/min,mL/min,CrCl less than 30 mL/min， use not recommended,Micromedex 20201015,202010151008,202010151006
OREOS,成人,Clcr,30.00,0,mL/min,mL/min,重度腎功能障礙（肌胺酸酐廓清率＜30ml/min）之患者不建議使用,仿單,202010150950,202010151006
OREX,成人,Clcr,60.00,0,mL/min,mL/min,MAX 2 mg once daily (major depressive disorder) or MAX 3 mg once daily (schizophrenia),Micromedex 20210330,202103301120,202103301121
ORIB,成人,Clcr,0,10.00,mL/min,mL/min,不建議使用,,201804150003,201804150003
ORIB,成人,Clcr,10.00,30.00,mL/min,mL/min,dosing should be reduced to a third of usual doses,,201804150003,
ORIB,成人,Clcr,30.00,60.00,mL/min,mL/min,A dose reduction of 50%,,201804150002,
ORIBA,成人,Clcr,0,29.99,mL/min,mL/min,decrease ribavirin to 200 mg ORALLY once daily and decrease peginterferon alfa-2a to 135 mcg SUBQ once weekly; do not attempt further decreases of ribavirin; if severe adverse reactions or laboratory abnormalities occur， discontinue ribavirin; if therapy is restarted and intolerance continues， discontinue regimen.,,,
ORIBA,成人,Clcr,30.00,50.00,mL/min,mL/min,decrease ribavirin to alternating daily doses of 200 mg and 400 mg ORALLY every other day,,,
ORIF3,成人,Clcr,0,10.00,mL/min,mL/min,50% of the normal daily dose,,,
ORIF3,成人,Clcr,10.00,50.00,mL/min,mL/min,50% to 100% of the normal dose,,,
ORIF5,成人,Clcr,0,0.99,mL/min,mL/min,chronic kidney disease or ESRD and HIV: peritoneal dialysis， 50% to 100% of the full dose， with an extra 50% to 100% of the full dose after peritoneal dialysis.,Micromedex 20210301,202103010859,
ORIF5,成人,Clcr,0,1.00,mL/min,mL/min,chronic kidney disease or ESRD and HIV: hemodialysis， 50% to 100% of the full dose with no supplement following hemodialysis.,Micromedex 20210301,202103010858,
ORIF5,成人,Clcr,0,50.00,mL/min,mL/min,chronic kidney disease or ESRD and HIV: CrCl 50 mL/min or less， 50% to 100% of the full dose,Micromedex 20210301,202103010857,
ORIFA,成人,Clcr,0,30.00,mL/min,mL/min,Pyrazinamide: 25 to 35 mg/kg orally 3 times a week,,201803230959,201803231006
ORIFA,成人,Clcr,0,9.99,mL/min,mL/min,Rifampin: 50% of the full dose,,201803230958,201803231006
ORIFA,成人,Clcr,10.00,50.00,mL/min,mL/min,Rifampin: 50% to 100% of the full dose,,201803230958,201803231006
ORIFI,成人,Clcr,0,9.99,mL/min,mL/min,Rifampin: 50% of the full dose,,201803231003,201803231004
ORIFI,成人,Clcr,0,30.00,mL/min,mL/min,Pyrazinamide: 25 to 35 mg/kg orally 3 times a week,,201803231004,201803231004
ORIFI,成人,Clcr,10.00,50.00,mL/min,mL/min,Rifampin: 50% to 100% of the full dose,,201803231003,201803231005
ORISD,成人,Clcr,0,30.00,mL/min,mL/min,Initial， 0.5 mg orally twice daily; increase dose in increments of no more than 0.5 mg twice a day， with increases to dosages above 1.5 mg twice a day occurring at intervals of at least 1 week,,201804142345,201804142345
OSAB,成人,Clcr,10.00,30.00,mL/min,mL/min,Decrease dose by 75%,,201804160500,201804160500
OSAB,成人,Clcr,30.00,50.00,mL/min,mL/min,Decrease dose by 50%,,201804160500,
OSAB,成人,Clcr,50.00,80.00,mL/min,mL/min,Decrease dose by 25%,,201804160500,
OSAM,成人,Clcr,0,10.00,mL/min,mL/min,不建議使用,,201804121434,201804121434
OSAN1,成人,eGFR,0,59.99,mL/min/1.73m2,mL/min/1.73m2,腎病症候群 為誘導緩解作用，建議劑量為成人每日每公斤體重 5 毫克。起始劑量不應超過每日每公斤體重2.5 毫克。 類風濕性關節炎 前6 週之治療的建議劑量為每日每公斤體重 3 毫克，分成兩次。不應該超過每公斤體重5 毫克。要達到最大的療效、新 體睦療程需要持續長達12 週。新體睦起始劑量為每日每公斤體重2.5 毫克、分成兩次給藥，並依照病患耐受性允許來增加治療劑量。 乾癬 建議起始劑量為每日每公斤體重2.5 毫克分成兩次。不應超過每公斤體重5 毫克。,,201804231705,
OSEB,成人,Clcr,0,0,mL/min,mL/min,血液透析病人:600 mg ORALLY every 96 hours，give after hemodialysis,,,
OSEB,成人,Clcr,0,29.99,mL/min,mL/min,600 mg ORALLY every 72 hours,,,
OSEB,成人,Clcr,30.00,49.99,mL/min,mL/min,600 mg ORALLY every 48 hours,,,
OSEF,成人,Clcr,0,5.00,mL/min,mL/min,single dose of 400 mg or 9 mg/kg at the end of each hemodialysis session,血液透析病人,,
OSEF,成人,Clcr,5.00,29.00,mL/min,mL/min,100 mg every 24 hours or 2.25 mg/kg every 24 hours,,,
OSEF,成人,Clcr,30.00,49.00,mL/min,mL/min,200 mg every 24 hours or 4.5 mg/kg every 24 hours,,,
OSEF,成人,Clcr,50.00,120.00,mL/min,mL/min,無須調整劑量,,,
OSELA,成人,Clcr,0,30.00,mL/min,mL/min,不建議使用,,201804141554,201804141555
OSER1,成人,Clcr,0,30.00,mL/min,mL/min,建議將劑量限制在最低範圍,,201804150040,201804150042
OSERM,成人,Clcr,10.00,25.00,mL/min,mL/min,重度腎功能不全的病患，其藥物排除下降，應注意調整劑量,,201804130657,201804130657
OSPI,成人,eGFR,30.00,49.00,mL/min/1.73m2,mL/min/1.73m2,起始劑量:12.5 mg orally once a day,維持劑量: 12.5mg~25 mg once a day after 4 weeks for potassium 5 mEq/L or less,201804120120,201804120121
OSPI,成人,eGFR,50.00,0,mL/min/1.73m2,mL/min/1.73m2,起始劑量:12.5 mg to 25 mg orally once a day,維持劑量:25 mg once or twice a day after 4 weeks for potassium 5 mEq/L or less,201804120117,201804120120
OSUL,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,Avoid use.(KDIGO 2012 guidelines),,201912091238,201912091238
OSUL,成人,eGFR,30.00,60.00,mL/min/1.73m2,mL/min/1.73m2,Temporarily discontinue in patients with intercurrent disease that increases risk of acute kidney injury.(KDIGO 2012 guidelines),,201912091237,201912091237
OSUL,成人,Clcr,0,0,mL/min,mL/min,明顯腎功能不全之病患，可減少每日劑量，避免藥物積蓄,,201804141600,
OSUN,成人,Clcr,0,0,mL/min,mL/min,血液透析病人:無須調整劑量,,,
OSUN,成人,Clcr,0,29.99,mL/min,mL/min,每日一次100mg,,,
OSUT,成人,eGFR,0,10.00,mL/min/1.73m2,mL/min/1.73m2,ESRD on hemodialysis: No initial adjustment required; subsequent dosage increases (up to twofold) may be required due to reduced (47%) exposure.,,201804301505,
OSYN1,成人,Clcr,0,20.00,mL/min,mL/min,禁用,仿單,202012021554,201804160606
OSYN1,成人,Clcr,20.00,30.00,mL/min,mL/min,正常劑量的1/6，每日一次服用,仿單,202012021554,201804160606
OSYN1,成人,Clcr,30.00,49.00,mL/min,mL/min,正常劑量的1/3，每日分兩次服用,仿單,202012021553,
OSYN1,成人,Clcr,50.00,79.00,mL/min,mL/min,正常劑量的2/3，每日分兩到三次服用,仿單,202012021553,
OSYNG,成人,Clcr,0,20.00,mL/min,mL/min,Use is contraindicated.,,202001081115,
OSYNG,成人,Clcr,20.00,30.00,mL/min,mL/min,Decrease to 1/6 of the normal daily dose administered once daily.,,202001081116,
OSYNG,成人,Clcr,30.00,49.00,mL/min,mL/min,Initial and maximum dose: Decrease to 1/3 of the normal daily dose administered in 2 divided doses.,,202001081116,
OSYNG,成人,Clcr,50.00,79.00,mL/min,mL/min,Initial and maximum dose: Decrease to 2/3 of the normal daily dose administered in 2 to 3 divided doses.,,202001081116,
OTAI,成人,Clcr,0,60.00,mL/min,mL/min,腎功能不全：中度至重度腎功能不全病人及末期腎臟疾病（ESRD）病人不建議使用本藥品。,仿單,202301111655,
OTAI,成人,Clcr,60.00,90.00,mL/min,mL/min,輕度腎功能不全病人（肌酸酐清除率【CLcr】60~90 mL/min）不須調整用藥劑量。,仿單,202301111655,202301111656
OTAM7,成人,Clcr,0,0,mL/min,mL/min,血液透析病人:30 mg orally immediately， then 30 mg after every hemodialysis cycle; treatment duration not to exceed 5 days from the time of the initial dose,,,
OTAM7,成人,Clcr,10.00,29.99,mL/min,mL/min,30 mg orally once daily for 5 days,,,
OTAM7,成人,Clcr,30.00,59.99,mL/min,mL/min,30 mg orally twice daily for 5 days,,,
OTAMI,成人,Clcr,0,0,mL/min,mL/min,血液透析病人:30 mg orally immediately， then 30 mg after every hemodialysis cycle; treatment duration not to exceed 5 days from the time of the initial dose,,,
OTAMI,成人,Clcr,10.00,29.99,mL/min,mL/min,30 mg orally once daily for 5 days,,,
OTAMI,成人,Clcr,30.00,59.99,mL/min,mL/min,30 mg orally twice daily for 5 days,,,
OTAN,成人,Clcr,0,30.00,mL/min,mL/min,建議將常用劑量減半或將投與間隔延長,,201804121553,201804121553
OTENO,成人,Clcr,0,15.00,mL/min,mL/min,最高劑量:25 mg ORALLY once daily,,201804121455,201804121455
OTENO,成人,Clcr,15.00,35.00,mL/min,mL/min,最高劑量:50 mg ORALLY once daily,,201804121454,
OTET2,成人,eGFR,0,9.99,mL/min/1.73m2,mL/min/1.73m2,Administer recommended dose based on indication every 24 hours.,,201812171106,
OTET2,成人,eGFR,10.00,50.00,mL/min/1.73m2,mL/min/1.73m2,Administer recommended dose based on indication every 12 to 24 hours.,,201812171105,
OTON,成人,Clcr,0,3.00,mL/min,mL/min,100 mg orally at extended intervals,,201804142316,201804142316
OTON,成人,Clcr,3.00,10.00,mL/min,mL/min,Do not exceed 100 mg orally daily,,201804142315,
OTON,成人,Clcr,10.00,20.00,mL/min,mL/min,200 mg orally daily,,201804142315,
OTOP5,成人,Clcr,0,70.00,mL/min,mL/min,Use 50% of the usual adult dosage,,201804160505,201804160505
OTRA2,成人,Scr,1.36,2.83,mg/dL,mg/dL,Maintenance dose of 10 mg/kg/dose twice daily,,201804231440,
OTRA2,成人,Scr,2.83,5.66,mg/dL,mg/dL,Maintenance dose of 10 mg/kg/dose once daily,,201804231440,
OTRA2,成人,Scr,5.67,99.00,mg/dL,mg/dL,Maintenance dose of 10 mg/kg/dose every 48 hours or 5 mg/kg/dose once daily,,201804231441,
OTRCT,成人,Clcr,0,30.00,mL/min,mL/min,增加本品的給藥間隔，每12小時不要超過兩錠。,仿單,202201111150,202201111151
OTRCT,成人,Clcr,0,30.01,mL/min,mL/min,Do not exceed 2 tablets every 12 hours,Micromedex 20220111,202201111149,202201111150
OTRIL,成人,Clcr,0,30.00,mL/min,mL/min,治療劑量應為一般起始劑量應為一半(每天300mg)，再逐漸增加劑量以達到理想的臨床效果,,201804160425,201804160425
OTRO,成人,Clcr,0,70.00,mL/min,mL/min,Use 50% of the usual adult dosage,[Micromedex 20200703],202007051227,202007051230
OTRO,成人,Clcr,0,69.99,mL/min,mL/min,在腎功能不全（肌酸酐清除率低於 70 mL/min/1.73 m2）患者中，建議使用一般成人用劑量的一半。,[仿單],202007011643,202007051229
OTS1,成人,Clcr,0,0,mL/min,mL/min,腎功能障礙脂患者應警慎投與 (因5-FU代謝J抑制劑gimeracil於尿液中之排除減少，使5-FU血中濃度上升),嚴重腎功能障礙患者不建議使用,201804261602,201804261605
OUFR,成人,Clcr,0,30.00,mL/min,mL/min,500 to 1000 mg orally every 24 hours (extended-release tablet),,201804160415,201804160415
OUFR,成人,Clcr,30.00,50.00,mL/min,mL/min,500 to 1500 mg orally every 24 hours (extended-release tablet),,201804160415,
OUFR,成人,Clcr,50.00,80.00,mL/min,mL/min,1000 to 2000 mg orally every 24 hours (extended-release tablet),,201804160415,
OUFU,成人,Clcr,0,0,mL/min,mL/min,腎功能障礙之患者應警慎投與(副作用可能加重),,201804261608,201903031533
OULT,成人,Clcr,0,30.00,mL/min,mL/min,建議增加給藥間隔，每12小時不要超過兩錠,,201804141535,
OURA,成人,Clcr,0,30.00,mL/min,mL/min,20 mg orally once daily at bedtime,,201804212351,201804212351
OURI2,成人,Clcr,0,30.00,mL/min,mL/min,嚴重腎功能障礙者不建議使用,,201804212324,201804212324
OURI2,成人,Clcr,30.00,50.00,mL/min,mL/min,建議以低劑量 2 mg 一天兩次 作為治療的開始劑量,,201804212321,
OURI2,成人,Clcr,50.00,80.00,mL/min,mL/min,輕度腎功能障礙者無須調整劑量,,201804212322,201804212322
OURI8,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,嚴重腎功能障礙者不建議使用,,201904080914,
OURI8,成人,eGFR,30.00,50.00,mL/min/1.73m2,mL/min/1.73m2,建議以低劑量 2 mg 一天兩次 作為治療的開始劑量,,201904080913,
OURI8,成人,eGFR,50.00,80.00,mL/min/1.73m2,mL/min/1.73m2,輕度腎功能障礙者無須調整劑量,,201904080913,
OUROD,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,do not use if GFR less than 50 mL/min,Micromedex 20210913,202109131600,202109131609
OUROD,成人,eGFR,50.00,99.00,mL/min/1.73m2,mL/min/1.73m2,increase dosing interval to every 8 to 16 hours.,Micromedex 20210913,202109131600,202109131610
OUROP,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,Avoid use,Micromedex 20200703,201804212354,202007030854
OUROP,成人,eGFR,50.00,99.00,mL/min/1.73m2,mL/min/1.73m2,increase dosing interval to every 8 to 16 hours (Micromedex 20200703) 100 to 200 mg every 8 to 12 hours (UpToDate 20200703),,201804212353,202007030856
OVAL,成人,Clcr,0,0,mL/min,mL/min,血液透析病人:帶狀皰疹:一天一次，每次1000mg;單純皰疹:一天一次，每次500mg;單純皰疹之預防:一天一次，每次250mg(免疫健全)，一天一次，每次500mg(免疫不全);須在血液透析完給藥,,,
OVAL,成人,Clcr,0,15.00,mL/min,mL/min,帶狀皰疹:一天一次，每次1000mg;單純皰疹:一天一次，每次500mg;單純皰疹之預防:一天一次，每次250mg(免疫健全)，一天一次，每次500mg(免疫不全),,,
OVAL,成人,Clcr,15.00,30.00,mL/min,mL/min,帶狀皰疹:一天兩次，每次1000mg;單純皰疹:一天兩次，每次500mg;單純皰疹之預防:一天兩次，每次250mg(免疫健全)，一天兩次，每次500mg(免疫不全),,,
OVEM,成人,Clcr,0,14.99,mL/min,mL/min,Use is not recommended.,,201812200952,
OVEP,成人,Clcr,0,14.99,mL/min,mL/min,Data not available; consider further dose reductions,,201804301530,
OVEP,成人,Clcr,15.00,50.00,mL/min,mL/min,Administer 75% of dose,,201804301530,
OVEP5,成人,Clcr,0,14.99,mL/min,mL/min,Data not available; consider further dose reductions,,201811051114,
OVEP5,成人,Clcr,15.00,50.00,mL/min,mL/min,Administer 75% of dose,,201811051115,201811051115
OVERZ,成人,Clcr,0,30.00,mL/min,mL/min,There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).,[仿單]尚不清楚abemaciclib在重度腎臟功能不全(CLcr<30 mL/min)、末期腎臟疾病或接受透析病人的藥物動力學數據。,202206201121,202206201123
OVERZ0,成人,Clcr,0,30.00,mL/min,mL/min,There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).,[仿單]尚不清楚abemaciclib在重度腎臟功能不全(CLcr<30 mL/min)、末期腎臟疾病或接受透析病人的藥物動力學數據。,202210241656,202206201123
OVES,成人,Clcr,0,30.00,mL/min,mL/min,建議劑量: 75 mg every 12 hours,,201804131628,201804131629
OVES,成人,Clcr,30.00,50.00,mL/min,mL/min,建議劑量: 150 mg every 24 hours,,201804131629,201804131630
OVESI,成人,Clcr,0,30.00,mL/min,mL/min,重度腎功能障礙者要謹慎給藥，每日不可多於 5 mg,洗腎患者不建議使用,201804212335,201804212337
OVESI,成人,Clcr,30.00,0,mL/min,mL/min,輕度及中度腎功能障礙者無須調整劑量,,201804212326,
OVGR1,成人,Clcr,0,30.00,mL/min,mL/min,嚴重腎功能不全患者的清除率會下降，因此應考慮使用25 mg的起始劑量。基於藥效及耐受性的考量，劑量可提高至50 mg或100 mg,,201804212234,
OVGRO,成人,Clcr,0,30.00,mL/min,mL/min,嚴重腎功能受損之患者的清除率會下降，因此應考慮使用25 mg的起始劑量。基於藥效及耐受的考量，劑量可提高至50 mg或100 mg,,201804212238,201804212238
OVIA1,成人,Clcr,0,0,mL/min,mL/min,嚴重腎功能不全者，應在醫護監督下給與,,201804191421,201804191421
OVIM,成人,Clcr,0,0,mL/min,mL/min,血液透析可有效清除血漿中的 Lacosamide。4 小時的血液透析治療後，應考慮補充最多 50%的劑量。,仿單,202008041021,202008031607
OVIM,成人,Clcr,0.01,0,mL/min,mL/min,Removed by hemodialysis; after 4-hour hemodialysis treatment， a supplemental dose of up to 50% should be considered.,UpToDate 20200803,202008041021,202008031611
OVIM,成人,Clcr,29.99,0,mL/min,mL/min,CrCl <30 mL/minute: Reduce dose to 75% of the maximum dose.,UpToDate 20200803,202008041021,202008031611
OVIM,成人,Clcr,30.00,0,mL/min,mL/min,CLCR低於30毫升/分鐘/1.73公尺2:建議減少最大劑量的25%。,仿單,202008041022,202008031607
OVIM,成人,Clcr,60.00,29.99,mL/min,mL/min,CrCl >=30 mL/minute: No dosage adjustment necessary.,UpToDate 20200803,202008041022,202008031613
OVIR3,成人,Clcr,0,9.00,mL/min,mL/min,血液透析患者:300mg，給藥間隔每7天一次;或者進行透析的12小時後,,,
OVIR3,成人,Clcr,10.00,29.00,mL/min,mL/min,300mg，給藥間隔每72至96小時,,,
OVIR3,成人,Clcr,30.00,49.00,mL/min,mL/min,300mg，給藥間隔每48小時,,,
OVIR3,成人,Clcr,50.00,200.00,mL/min,mL/min,300mg，給藥間隔每24小時,,,
OVIS2,成人,Clcr,0,0,mL/min,mL/min,重度腎功能不全患者應謹慎使用,,201804242316,201804242316
OVOC,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,重度腎功能不全的病人不建議使用福星定膜衣錠20mg每天2次。 Severe impairment (estimated GFR less than 30 mL/min): Avoid use,仿單、Micromedex (2022.10.05),202210051957,202210051959
OVYT,成人,Clcr,0,30.00,mL/min,mL/min,每日劑量超過 10/10mg 時，應小心使用,,201804130742,201804130742
OWELX,成人,eGFR,0,90.00,mL/min/1.73m2,mL/min/1.73m2,Consider reducing dose and/or frequency of dosing,,201804160332,
OWIT1,成人,Clcr,5.00,29.00,mL/min,mL/min,reduce dosage to 5 mg orally twice daily,Micromedex 2020.06.18,202006181220,202006181222
OWIT1,成人,Clcr,30.00,80.00,mL/min,mL/min,No adjustment necessary,Micromedex 2020.06.18,202006181221,202006181222
OXAR,成人,Clcr,0,15.00,mL/min,mL/min,Avoid use.,,201804191202,
OXAR,成人,Clcr,15.00,30.00,mL/min,mL/min,Nonvalvular atrial fibrillation:15 mg once daily with the evening meal,仿單建議避免使用,201911251230,201911251234
OXAR,成人,Clcr,15.00,50.00,mL/min,mL/min,Nonvalvular atrial fibrillation:15 mg once daily with the evening meal,,201804191203,
OXAR1,成人,Clcr,0,15.00,mL/min,mL/min,Avoid use.,,201804191211,
OXAR1,成人,Clcr,15.00,50.00,mL/min,mL/min,Nonvalvular atrial fibrillation:15 mg once daily with the evening meal.,,201804191211,
OXAR25,成人,Clcr,14.99,0,mL/min,mL/min,CrCl less than 15 mL/min: Avoid use,Micromedex 20201217,202012171447,202012180919
OXAR25,成人,Clcr,15.00,0,mL/min,mL/min,CrCl < 15 mL/min 之病人禁止使用本品。,仿單,202012171445,
OXEL,成人,Clcr,0,29.90,mL/min,mL/min,Use is contraindicated.,,201803191621,
OXEL,成人,Clcr,30.00,50.00,mL/min,mL/min,Reduce dose to 75% of usual dose.,,201803191620,
OXELJ,成人,eGFR,0,59.99,mL/min/1.73m2,mL/min/1.73m2,Moderate to severe impairment: Reduce dose to 5 mg (immediate release) once daily. A supplemental dose after dialysis is not necessary in patients with severe impairment on dialysis.,,201804231707,
OXIG,成人,eGFR,0,45.00,mL/min/1.73m2,mL/min/1.73m2,避免使用,,202002101136,202002101136
OXIG,成人,eGFR,46.00,99.00,mL/min/1.73m2,mL/min/1.73m2,無須調整劑量,,201812261205,202002101136
OXOFL,成人,Clcr,0,30.00,mL/min,mL/min,[仿單]目前尚無重度腎功能不全病患(CrCl <30 mL/min)投與本藥後的藥物動力學資料,,202001071010,202001071011
OXOFL,成人,Clcr,30.00,60.00,mL/min,mL/min,[仿單]輕度或中度腎功能不全(CrCl >=30 mL/min)的患者，不需要調整劑量。,,202001071011,202001071521
OXTA,成人,Clcr,0,30.00,mL/min,mL/min,Preexisting severe impairment (CrCl <30 mL/minute)， including end-stage renal disease (ESRD): There are no dosage adjustments provided in the manufacturer's labeling.,,201803301704,201803301705
OXTA,成人,Clcr,30.00,89.00,mL/min,mL/min,Preexisting mild-to-moderate impairment (CrCl 30 to 89 mL/minute): No initial dosage adjustment necessary.,,201803301706,201803301705
OXYZ,成人,Clcr,0,9.99,mL/min,mL/min,CrCl <10 mL/minute， hemodialysis patients: Use is contraindicated.,,201804231521,201804231521
OXYZ,成人,Clcr,10.00,30.00,mL/min,mL/min,2.5 mg twice weekly (every 3 or 4 days),,201804231521,
OXYZ,成人,Clcr,30.00,50.00,mL/min,mL/min,2.5 mg once every other day,,201804231520,
OXYZ,成人,Clcr,50.00,80.00,mL/min,mL/min,2.5 mg once daily,,201804231519,
OYAZ,成人,Clcr,0,0,mL/min,mL/min,腎功能損傷患者不建議使用,,201804231351,201804231351
OZAN,成人,eGFR,0,30.00,mL/min/1.73m2,mL/min/1.73m2,禁用於有重度之肝功能不全病人或重度腎功能不全病人(GFR < 30 ml/min)，包括正在接受血液透析或腹膜透析的病人,仿單,201804121532,202007290924
OZAN,成人,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,本藥曾在腹膜透析病人身上出現混濁的腹膜透析流出液。此混濁現象肇因於腹膜透析流出液中較高的三酸甘油酯濃度。機制不明，但此停用lercanidipne後迅速消失。有可能將混濁的腹膜透析流出液誤認為感染性腹膜炎，進而造成不必要的住院及經驗性抗生素施用。,仿單,202007290931,202007290934
OZCO,成人,eGFR,0,50.00,mL/min/1.73m2,mL/min/1.73m2,There are no dosage adjustments provided in the manufacturer's labeling.,,201804191026,
OZES,成人,Clcr,0,10.00,mL/min,mL/min,起始劑量為2.5 mg/天,包含透析病人,201804121600,201804121601
OZES,成人,Clcr,10.00,30.00,mL/min,mL/min,起始劑量為2.5~5 mg/天,,201804121600,
OZES,成人,Clcr,31.00,80.00,mL/min,mL/min,起始劑量為5~10 mg/天,,201804121559,
OZIT,成人,Clcr,0,9.00,mL/min,mL/min,應謹慎用藥,,,
OZIT,成人,Clcr,10.00,80.00,mL/min,mL/min,無須調整劑量,,,
OZON1,成人,Clcr,0,0,mL/min,mL/min,腎功能不全患者治療時應謹慎，可能需要減慢調高zonisamide劑量的速度,,201804160511,201804160511
OZUL,成人,eGFR,0,0,mL/min/1.73m2,mL/min/1.73m2,Hemodialysis: Initial， 1 mg orally once daily; MAX， 2 mg/day,Micromedex 2020/06/08,202006081158,202006081158
OZUL,成人,eGFR,15.00,29.00,mL/min/1.73m2,mL/min/1.73m2,severe， GFR 15 to 29 ， not receiving hemodialysis: Initial， 1 mg orally once daily; MAX， 2 mg/day,Micromedex 2020/06/08,202006081159,202006081159
OZUL,成人,eGFR,30.00,59.00,mL/min/1.73m2,mL/min/1.73m2,moderate， GFR 30 to 59: Initial， 1 mg orally once daily; MAX， 2 mg/day,Micromedex 2020/06/08,202006081200,202006081159
